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Intlammation is an essential response of the host from infection or tissue invasion
and it plays an important role in health and disease. The immune system exerts tight
control on the inflammatory response, and most of the time elimination of
microorganisms occur with no clinically detectable signs of intlammation (Heumann
2002). However, in certain conditions, such as bacterial infection of the dental pulp,
the inflammatory process stimulates localized pathological processes which results
initially in pulpal destruction and ultimately in the development of a periradicular
lesion accompanied by bone resorption (Stashenko 1994). Gram-negative anaerobes,
which contain lipopolysaccharide (LPS or endotoxin) in their cell walls, are the
predominant bacteria involved in endodontic infections (Moller 1981). In samples
taken from necrotic pulp (Dahlen 1980) and from the dentin wall of periapically
involved teeth (Horiba 1990), the presence of LPS has been reported; thereby,
establishing its role in periapical bone resorption. It has also been shown that levels
of LPS increased with time after periapical lesion induction in rats (Yamasaki 1992)
and in other animal models, application ofLPS to dental pulp initiated and sustained
apical periodontitis (Dahlen 1981).
LPS is the major component ofthe outermost membrane of Gram-negative
bacteria and was the first component of bacteria shown to induce bone resorption
(Lynn 1992). It is a complex glycolipid which consists of a variable polysaccharide
domain covalently bound to a diglucosamine based acylated phospholipid, lipid A.
(Raetz 1990). lbe lipid A portion of LPS is highly conserved between different
strains of Gram-negative bacteria, has been shown to have LPS agonist activity;
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therefore, it is thought to be responsible for most of the biological effects ofLPS.
(Morrison 1987).
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LPS Recogniton
Until 1990, little was known about the protein molecules that specifically
recognized LPS and initiated a host response, It was thought that immune cells were
activated by LPS through spontaneous intercalation of lipid A into the mammalian
lipid bilayer (Lynn 1992). This concept was repudiated with the cloning and
sequencing of lipopolysaccharide-binding protein (LBP) by Schumann et al in 1990
(Schumann 1990). LBP is a 60kd serum glycoprotein produced in the liver and
catalyzes the transfer of bacterial membrane LPS to its receptor, CD14 from the outer
membrane (Schumann 1990). It contains a high affinity binding site for lipid A,
opsonizes particles bearing LPS, and mediates macrophage attachment to these
particles (Schumann 1990). Normal serum contains LBP at quantities of less than

0.5ug/ml, with a rise to 50ug/ml within twenty-four hours after an acute phase
response (Schumann 1990). LBP has been shown to be specifically involved in
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recognizing the products of pathogenic bacteria. (Schumann 1996). LPS processing
by LBP and CD 14 not only initiates a LPS response, it also facilitates clearance of
LPS (Miyake 2004). Both LBP and CD14 can cause LPS to lose its biological
activity by delivering LPS to high-density lipoprotein (HDL) particles where it is
then excreted by the liver (Miyake 2004).

CD14
CD14 is an opsonic receptor for complexes ofLPS (or LPS-containing particles
such as bacteria) and LBP (Aderem 2000). It is either present on the surface of
monocytes/macrophages and PMN's as a glycosylphoshatidylinositol-anchored
molecule (OPI) membrane CD14 (mCD14) or is present in the circulation as a soluble
molecule (sCD14) and lacks the OPI structure (Bazi11989). It was discovered in
1990 by Wright, et aI, and has also been implicated in cell activation processes that
involve other products of microbial pathogens. Studies have found that CD 14
functions solely as a ligand-binding protein, it does not participate in the generation
of transmembrane signals and few details are known about the structure of the ligand
binding pocket of this protein (Delude 1995). However, it was hypothesized that one
or more additional transmembrane proteins acted together with LPS-CD 14 complexes
to initiate the signaling processes leading to cell activation. Identification of this
transmembrane protein was unsuccessful until the discovery of the Toll-like receptors
(TLRs). It has been clearly shown that LPS signal transduction begins on the cell
surface by cells that have abundant CD14 and TLR4IMD-2 (Visintin 2003).
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Toll-like Receptors
Toll (or TLRs) is the human homologue of the Drosophila Toll which was
successfully cloned in 1997 (Medzhitov). They are type-l transmembrane proteins
with their cytoplasmic domain very similar to the human IL-1 receptor. The
cytoplasmic domain also contains a signaling domain known as Toll-interleukin (IL)1 receptor (TIR) domain. The TIR domain is common to all TLRs as well as the IL-1
receptor family (Miyake 2004).
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TLR2 was first identified as the main LPS receptor (Yang 1998); however, further
studies revealed that these reports were flawed. LPS preparations used in these
experiments were contaminated with bacterial lipoproteins which activate TLR2
(Hirschfeld 2000). It is now known that TLR4 is the primary TLR responsible for
responses to LPS. C3H/HeJ mice, which are insensitive to LPS, were shown to have
a single point mutation in the TIR domain ofTLR4 and another LPS-insensitive
mouse strain, C57BLllOScCr was shown to have a null point mutation in the TLR4
gene thus providing the evidence that TLR4 was the receptor for LPS (Poltorak
1998). However, recent studies have indicated that other types of LPS, in particular
LPS of Leptospira interrogans (Werts 2001), Porphymonas gingivalis (Bainbridge
2001), and Neisseria meningitides (Pridmore 2001) involve TLR2 for cell activation.
TLR4 works downstream ofCD14, and delivers the LPS signal (Miyake 2004).
There are four TIR-domain-containing adapter molecules that mediate the signaling
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ofTLR4, with all four sharing significant similarity of their amino acid sequencing
in their TIR domain: 1. Myeloid differentiation factor 88 (MyD88) (Muzio 1997).
2. MyD88 adapter like (Mal), also called TIR-domain-containing adapter protein
(TIRAP) (Fitzgerald 2001). 3. TIR-domain-containing adapter inducing interferonB (TRIF), also called TIR-domain-containing adapter molecule-l (TICAM-1)
(Yamamoto 2002). 4. TRIF-related adapter molecule (TRAM), also called TIRcontaining protein (TIRP) or TIR-containing adapter molecule (TICAM-2) (Oshiumi
1998). Unlike other TLR's that use some of these adapter molecules, TLR4 requires
all four to initiate a comprehensive immune response. (Fitzgerald 2004). It is
currently thought that the propagation of LPS signaling is achieved following the
recruitment of these four TLR-domain containing adapter molecules. They provide a
structural platform that activate downstream kinases, which ultimately leads to the
activation of specific transcription factors and inflammatory gene expression.
MyD88 was first identified as a gene that was induced during IL-6 stimulated
differentiation ofMl myeloleukemic cells into macrophages and then cloned as a TIR
and death domain (DD)-containing protein. It is recruited to the C-terminal TIR
domain of the IL-1R and then recruits the serine/threonine kinase IL-IR-associated
kinase-l (IRAKl) through its N-terminal DD (Muzio 1997). Not only does it interact
with the IL-IR, it is brought to the TIR domain of other TLR families with the
exception ofTLR3; therefore, MyD88 is a shared component ofIL-IR1TLR signaling
(Kawai 1999). Mice, deficient in MyD88, were insensitive to LPS-induced death and
failed to release IL-6 and tumor necrosis factor alpha (lNF-a) in vivo, or in LPSstimulated macrophage cultures in vitro (Kawai 1999). The existence of an MyD88
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independent pathway to signal TLR4 was also identified after nuclear factor kappa
beta

(NFk~)

translocation and phosphorylation of mitogen-activated protein kinases

occurred in these MyD88 deficient mice, although delayed, it was not eliminated
(Kawai 1999). Unpublished results suggest that MyD88-independent signaling may
be responsible for the majority ofthe LPS response (Fitzgerald 2004).
Mal or TIRAP is another TIR-domain-containing protein which mediates the
signaling ofTLR4 but not IL-IR ( (Fitzgerald 2001). It has the C-terminal TIR
domain but not the N-terminal DDpresent in MyD88. Mal-deficient macrophages
have severely impaired LPS-induced cytokine production with normal responses of
the TLRS,TLR7, TLR9, IL-l and IL-18 receptors (Yamamoto 2002).
There is no LPS- induced cytokine gene expression in TRIF or TICAM-l
deficient macrophage cultures; however, there is normal cytokine expression via
TLR2, TLR7 and TLR9 (Fitzgerald 2003).
TRAM associates with TLR4 and TRIF. It has been shown that TRAM and TRIF
regulated MyD88 independent signaling (Fitzgerald 2003). Studies of TRAMdeficient mice show that TRAM is essential for the MyD88 independent signaling
pathway (Yamomoto 2003). TRAM-deficient mice also have defective induction of
inflammatory cytokines from LPS (Fitzgerald 2003).
Although TLR4 is essential for LPS signaling, studies suggested that an additional
molecule was required. Human embryonic kidney (HEK)-derived 293 cells and
mouse IL-3 dependent pro-B cell line BaJF3 did not have the ability to respond to
LPS after in vitro transfection ofTLR4 cDNA (Shimazu 1999). This
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unresponsiveness was explained through the discovery of an additional component of
the LPS recognition complex, MD-2 (Shimazu 1999).
MD-2
MD-2 is an 18 kDA protein that is bound to TLR4 in the Golgi and also found as a
soluble molecule that is secreted by MD-2 expressing cells (Visintin 2001). It is
absolutely necessary for LPS recognition and it must be physically associated with
TLR4 for this recognition to occur (Miyake 2004). The association between these
two proteins occurs in the endoplasmic reticulum (ER) and studies have also sho'h'll
that gp96, an ER chaperone, plays an important role (Visintin 2001). The exact
binding site ofTLR4 to MD-2 is not kno\\'ll, and neither is the exact location of the
LPS to MD-2 binding site (Miyake 2004). Some of the amino acids crucial for MD-2
interaction with TLR4 have been identified (Visintin 2003). It has been shown in
vitro that cells which express TLR4 alone or with a mutant tvID-2, are hyporesponsive
to LPS (Shimazu 1999). It has also been shown that a lack of response to LPS can be
altered with transfection ofMD-2 eDNA or soluble MD-2 protein (Schromm 2001).
In vitro studies using cells that lack mouse MD-2 have sho\\'ll an important role
for MD-2 in TLR4 cell surface expression. Murine fibroblasts that were MD-2
deficient, temporarily expressed mouse TLR4 stacked in the Golgi apparatus. In
wild-type fibroblast cells, TLR4 moved beyond the Golgi apparatus to the cell
surface. These same results have also been described for human MD-2 (Nagai 2002).
Gp96 has also been sho\\'ll to play an important role in the expression ofTLR4-MD-2
on the cell surface Gp96-deficient cells do not form the TLR4-MD-2 heterodimer
(Randow 2001).
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LPS Signal Transduction

It is thought that LPS activation of nuclear factor kappa beta

(NFK~),

a group of

transcription factors necessary for innate and adaptive immunity, via TLR4 occurs
through a signaling pathway that is also utilized by IL-l (Yang 2000). The binding
of MyD88 to the TIR domain ofTLRs mediates their signal transduction. MyD88
contains a C-terminal Toll homology which interacts with the Toll domain of the
receptor, and an N-terminal death domain. Its death domain interacts with the death
domain of an IL-I receptor associated kinase (IRAK), leading to the
autophosphorylation ofIRAK (Aderem 2000). IRAK can now complex with an
adaptor, TNF receptor associated factor (TRAF) 6 which then activates transforming
growth factor beta

(TGF~)-activated

protein kinase-l (TAK-l), a member of the

mitogen-activated protein (MAP) kinase family, though the details of this pathway
are less clear (Aderem 2000). The activation ofTAK~l activates the I K~ kinases
(IKK) which in turn phosphorylates the inhibitory proteins,

IK~,

causing their

proteolytic degradation and the translocation ofNF-K~ to the nucleus (Aderem 2000)
where transcription is activated. The role of MyD88 and TRAF6 in LPS signaling
have been confirmed genetically with the inability to respond to LPS in MyD88deficient mice (Kawai 1999). TRAF -6 deficient mice are also hyporesponsive to LPS
(Lomaga 1999). This data, taken together, indicates a role in LPS signaling in
monocytes and macrophages for MyD88, IRAK and TRAF6 (Li 2000).
IKKn and IKK~ are the two kinases (IKK) responsible for phosphorylating IkWs
(May 1999) and they form a large multiprotein complex with NEMO (IKK y), a
scaffold protein (Yamaoka 1998). The activation of these two kinases is thought to
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be through phosphorylation by an upstream kinase. NF-KP inducing kinase (NIK)
and mitogen-activated protein kinase ERK kinase kinase 1 (MEKK» are both
candidates for this role because each of these can activate NF -KP through
phosphorylation and activation of the IKKs (Lee 1997). In addition, LPS activation
ofNF-KP and TNF-a promoter activity in mouse RAW 264.7 cells was inhibited in
dominant negative mutants ofNIK, MEKKl, and TAK-l (Swantek 1999). It has
been shown that LPS activates the IKKs in human monocytes, THP-I monocytic cells
and mouse RAW 264.7 cells (O'Connell 1998). Activation of IKK's by LPS was
relatively slow - peaking at about thirty minutes - when compared with TNF-a
activation of the IKKs - peaking at about five minutes. This suggests involvement of
different signaling pathways by these two agonists (Hawiger 1999). Further study
has shown that LPS induction ofNF-KP gene expression and TNF-a promoter activity
is inhibited by a dominant-negative mutant of IKKP and that a dominant-negative
mutant ofIKKa had no effect (O'Connell 1998). Knock-outs ofIKKa genes result in
abnormal morphogenesis, whereas knock-outs ofIKKP genes results in embryonic
lethality caused by severe liver degeneration during midgestation, a phenotype
consistent with excess TNF-a toxicity (Beg 1995). From these results and from
studies using IKK-aand IKK-P deficient fibroblasts, it was concluded that IKKP but
not IKKa was required for TNF -aand IL-l signaling and that IKK -~ is required for
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The IL-l receptor associated kinases, IRAK (Cao et aI1996), lRAK-2 (Muzio et al
1997), IRAK-3 (Wesche et aI., 1999) , and IRAK-4 (Li 2002) comprise the
serine/threonine kinase family. They were first described in 1994 (Martin 1994),
cloned in 1996 (Cao 1996), and are important mediatiors of ToU/IL-l receptor family
signal transduction (Kollewe 2002). IRAK and IRAK-4 are active kinases, and
IRAK-2 and IRAK-3 are the two inactive or inhibitory kinases. IRAK-3 is found
only on macrophages/monocytes. When stimulated by TLRs, IRAK is recruited to
the TLR signaling complex (Medzhitov 1998).

Osteoblasts
Osteoblasts are bone forming cells that originate from mesenchymal tissue and are
nearly indistinguishable from fibroblasts in cell culture. Mature osteoblasts, which are
aligned on the bone surface, are responsible for the secretion and deposition of most
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of the bone matrix proteins such as type I collagen, osteocalcin, osteonectin,
osteopontin, bone sialoprotein and proteoglycans. Another component of bone,
hydroxyapatite crystals in osteoid, is also regulated by osteoblasts. Therefore, major
functions of osteoblasts include: the expression of a number of bone-related
extracellular matrix proteins, high enzyme activity of alkaline phosphatase (ALP),
and responses to osteotropic hormones and cytokines (Katagiri 2002).
Osteoblast differentiation can occur through two distinct pathways during
embryonic development: endochondral ossification or intramembranous ossification
(Horton 1993).
Ostoblasts differentiate directly from mesenchymal cells during intramembranous
ossification. During endochondral ossification, chondrocytes differentiate from
mesenchymal cells and form a cartilaginous template. After maturation of
hypertrophic chondrocytes in the template, osteoblasts are immediately formed from
the surrounding mesenchymal cells (Chung 1998). The processes of bone and
cartilage formation may mean that theses tissues are derived from a common
progenitor cell. Calvaria or bone marrow cell cultures showed mixed populations of
osteoblasts, chondrocytes, adipocytes and skeletal muscle cells (Taylor 1979). The
formation of these tissue-specific cells indicate that a pluripotent progenitor is
capable of differentiation (Grigoriadis 1998). The mineralized extracellular matrix is
the only morphological feature specific to osteoblasts; however, the genes responsible
for this matrix have not been found to be selectively expressed in osteoblasts (Ducy
2000).
Regulation of osteoblast differentiation
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In the search for the "master" regulators of ostoblast differentiation, two
osteoblast-specific cis-acting elements (OSEs) were identified in the promoter of the
Osteocalcin gene (Bgp): OSEI and OSE2. Cbfal, which binds to OSE2, was then
identified as the first osteoblast-specific transcription factor (Ducy 1997). It is an
important and necessary gene for osteoblast differentiation and is one of the earliest
and most specific markers of osteogenesis (Ducy 2000). It is homologous to one of
the three Drosophila runt and lozenge proteins ((Speck 1995). Cbfal expression
precedes osteoblast differentiation during embryonic development and it is restricted
to mesenchymal cells that will eventually become chondrocytes or osteoblasts (Duey
1997). Its expression subsequently becomes limited to osteoblasts, with a lower level
of expression in hypertrophic chondrocytes (Kim 1999). Odontoblasts, dentinsynthesizing tooth homo logs of osteoblasts, also express Cbfal (D'Souza 1999).
Cbfal is an activator of transcription and induces osteoblast-specific gene
expression in fibroblasts and myoblasts (Ducy 1997). Mice, deficient in Cbfa-l,
develop full term with a normal skeleton made exclusively of cartilage: osteoblast
differentiation never occurs (Komori 1997), and certain bones show defects in
hypertrophic chondrocyte differentiation (Kim 1999). These mice also lack
osteoclasts because osteoblasts are required for osteoclast differentiation. Upstream
expression control of Cbfal has not been identified. Gene deletion experiments in
mouse models, suggest that it is controlled in the developing skeleton by different
transcription factors at different locations. It is also not known what transcription
factors act downstream of Cbfal (Oucy 2000).
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OSE], the other cell-specific regulatory element in the Osteocalcin promoter, is as
important as the Cbfal binding site for Osteocalcin expression (Schinke 1999). The
factor that binds OSE1, has been biochemically characterized recently, but its
complete identification will help to further define the genetic pathways controlling
osteoblast differention (Ducy 2000). It is also possible that new transcription factors
important for osteoblast differentiation may be identified through broad-based gene
deletion experiments (Ducy 2000).
Osteoblast differentiation during embryonic development involves members of all
the major families of growth factors. Expression of Cbfal can be induced in vitro by
several bone morphogenetic proteins; however, it appears to be through indirect
action and is of unknown physiological relevance (Ducy 1997). In cultured
osteoblasts, the steady state level of osteoblast differentiation in vivo and inhibition of
Cbfal expression can be controlled by transforming gro\vth factor- beta

(TGF-~).

The mechanism through which this occurs is unkno\\'TI (Ducy 2000).
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Bone Morphogenetic Proteins

When pulverized bone organic matrix is implanted into muscular tissue it induces
ectopic bone formation as was described by Urist in 1965 (Urist 1965). These
proteins were eventually named 'BMPs" after their cDNA was isolated (Wozney
1988). Ectopic bone formation has been shown to be induced by BMP proteins
(Kingsley, 1994) and this activity is unique to BMPs among the growth factors.
BMPs, except BMP-l, belong to the TGF-p family of growth factors, regulate the
proliferation, differentiation and death of cells in various tissues (Hogan 1996), and
are believed to be secreted and deposited by osteoblasts into the extracellular matrix
during bone formation.
The hypothesis that BMPs regulate osteoblast and chondrocyte differentiation
during skeletal development was confirmed with the identification of skeletal
abnormalities in animals and patients with mutations in the BMP genes. Mutation in
BMP-5, the mutant mouse 'short ear' was the first example to be sho\\;TI by Kingsley
in 1992 (Kinglsey 1992). He showed that the BMP-5, which is deleted or rearranged
in several independent mutations at the short ear locus, was encoded in the short ear
region. However, whether BMPs are involved in bone and cartilage formation after
birth is still unclear (Katagiri 2005).
Transcriptional control of bone formation

In addition to its role during osteoblast formation, Cbfal also controls bone
formation. It regulates the expression ofOsteoclacin (Bgp), a gene that is expressed
only in terminally differentiated osteoblasts (Duey 2000). Genes required for the
formation of bone extracellular matrix contain cbfal binding sites (Duey 1997) and
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transgenic mice experiments show that the rate of bone formation by differentiated
osteoblasts are controlled by CbfaI (Ducy 1999).
Osteoblasts regulate osteoclast differentiation

Osteoclast development occurs within the microenvironment of bone in response
to a variety of osteotropic factors including I,25-dihydroxyvitamin D3 (1,250H)2D3,
PTH, prostaglandin

(PGE2) and interleukin 11 (IL-II). The earliest identified

osteoclast progenitor in bone marrow has been phenotyped as a c-Kit+/c-FmsICDIlb-/RANK- cell which then differentiates into a c-Kit+/c-

Fms+/CD 11 b+IRANK- early stage progenitor (Boyce 2005) This cell, termed a late
stage progenitor, then becomes RANK+ upon stimulation by M-CSF. It responds to
RANKL to complete osteoclast development (Boyce 2005). To investigate the
regulatory mechanisms of osteoclast differentiation, osteoblasts/stromal cells and
hematopoietic cell cocultures were developed (Takahashi 1988).

The

multinucleated cells that formed expressed tartrate-resistant acid phosphatase (TRAP
- a marker enzyme of osteoclasts), calcitonin receptors, vitronectin recepors and the
ability to form resorption pits on bone and dentine slices (Katagiri 2002).
Osteoclastogenesis requires cell-to-cell contact between osteoblasts/stromal cdls and
osteoclast progenitors (Jimi 1996). Osteoblast/stromal cells are the targets of
osteotropic factors to induce osteoclastogenesis (Udagawa 1995).
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Osteoclasts - Origin and Cell Lineage
Osteoclasts, tissue-specific macrophage polykaryons, are created from
monocyte/macrophage precursor cell differentiation at or near the bone surface
(Boyle 2003). Their hematopoietic origin was demonstrated in transplantation
studies (Croccia 1980). In vivo (Baron 1986) and in vitro studies (Schneiderl988)
initially suggested that osteoclasts were derived from mononuclear phagocytic cells;
however, although macrophages and osteoclasts share a common precursor, these
lineages diverge upon further differentiation (Hagenaars 1989). Compared to cells of
the macrophage series, they possess a distinct phenotype and functional capabilities,
in particular, resorbing bone (Zhao 2007). Our understanding of osteoclastogenesis
was advanced when co-cultures of bone marrow or spleen cells and stromal cells
from murine systems yielded osteoclasts (Takahashi 1988). It was determined that
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stromal-derived factors stimulated this process because of the need for close contact
between osteoblasts/stromal and bone marrow cells, and it is now known that these
cells express the polypeptide growth factor, macrophage colony-stimulating factor
(M-CSF) and the cytokine IL-6 that induce and control growth and differentiation of
the precursors to mature osteoclasts (Burger 1984). Calcitrol, the vitamin D
metabolite, and the parathyroid hormone also support development of osteoclasts
(Suda 1992). Multiple Golgi complexes and numerous mitochondria are present in
the osteoclast precursor cells (Baron 1986). "Preosteoclasts", a term which is used to
describe a mononuclear precursor that shows morphological and cytochemical
features similar to those of multinucleated osteoclasts, will differentate from
osteoclast precursors in a suitable microenvironment (Scott 1967). Ready to fuse into
multinucleated osteoclasts upon further differentiation, these cells are TRAP-positive
and express mRNAs for all osteoclast-associated phenotypes which include: TRAP,
calcitonin receptor (CTR) and cathepsin K (Scheven 1986). A highly specialized
proton-generating pump found in osteoclasts rapidly dissolves minerals, secretes
collagenases, (Wucherpfennig 1994) cathepsin K ( Li 1995)and other hydrolases
involved in the degradation of bone matrix proteins.

M-CSF and RANKL are both

needed to induce gene expression of the osteoblast lineage which leads to mature
osteoclast development (Lacey 1998).
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Osteoclast gene transcription
It has been shown that at least twenty-four genes or loci positively and negatively

affect osteoclastogenesis and osteoclast activation (Boyle 2003). These findings are
based on naturally.occurring mutations or targeted knockout mutations in humans and
rodents which show blocked development and/or function of the mature osteoclast
resulting in osteopetrosis when these genes are disrupted (Mark 1998). The effects of
these genes are expressed at different stages of osteoclast development and activation,
and the gene products for some these loci have still not been identified (Boyle 2003)
The genes PU.1 and op/CSF-l act during the formation and survival of the osteoclast
precursor cell. Essential for the development of myeloid and lymphoid lineage cells,
PU.l is a EST-domain transcription factor. PU.l is thought to regulate lineagespecific cytokine receptor genes, such as M-CSF receptor (c-fms), GM-CSFRalpha,
G-CSFR, and IL-7Ralpha (Singh 1999).
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The earliest established event in osteoclastogenesis is regulated by PU .1. The
expression of PU.1 is detected at all stages of osteoclast differentiation. As cells
differentiate into osteoclasts, PU.1 mRNA increases 3-fold (Tondravi 1997)
Embryonic stem (s) cell disruption of PU.1 causes lack of macrophages and
osteoclasts with osteopetrosis (Tondravi 1997). Corresponding sequences in the
promoters and enhancers of many osteoclast specific genes are bound to by PU, 1.
The RANK gene is a transcriptional target of PU.1. Failure of expression of the
RANK gene is seen in PU.1-/- progenitor cells; however, reconstitution of PU.1
induced RANK expression (Kwon 2005). PU.l and NF ATc 1 together regulate
RANKL-induced cathepsin K gene expression (Matsumoto 2004). Tartrate-resistant
acid phosphatase gene expression is activated in osteoclasts due to the interaction of
micropthalmia associated factor (Mitif), a transcription factor, and PU.1 with the
tartrate-resistant acid phosphatase (TRAP) gene promoter (Partington 2004).
Therefore, PU.1 is a master regulator that is critical for development of a common
progenitor for the lymphoid myeloid cell lineages in the hematopoietic system (Zhao
2007).

Receptor activator of NFKB (RANK) Signaling and Osteoclastogenesis

RANK, the receptor for RANKL, is a member of the tumor necrosis factor (TNF)
receptor family and is involved in osteoclastogenesis and lymph node development
(Anderson 1990). It is expressed as a transmembrane heterotrimer on the surface of
hematopoietic osteoclast progenitors, mature osteoclasts; chondrocytes and mammary
gland epithelial cells (Anderon 1997). RANKL interacts with RANK via direct cell
to cell contact, thereby promoting the differentiation, survival, and bone-resorbing
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capability of osteoclasts (Suda 1999). It has been shown that mice, genetically
deficient in either RANK or RANKL show a profound defect in osteoclastogenesis
which results in severe osteopetrotic phenotype (Kong 1997). Cytokines such as MCSF and RANKL that initiate and control the growth and differentiation of the
precursors to mature osteoclasts are produced by osteoblasts/stromal cells (Zhao
2007). The binding ofM-CSF to its receptor, c-Frns, present on osteoclast precursors
provides the macrophage survival and proliferation signals. The expression of
osteoclast-specific genes during differentiation, the activation of resorption by mature
osteoclasts, and their survival and participation in bone degradation at neighboring
sites is activated by the RANKlRANKL interaction (Boyle 2003). Cytoplasmic
factors that activate downstream signaling pathways that control these various
functions mediate RANK signaling. At least five distinct signaling cascades
mediated by protein kinases are induced during osteodastogenesis and activation inhibitor ofNF-K~ kinase (IKK), c-Jun N-terminal kinase (JNK), p38, extracellular
signal-regulated kinase (ERK) and Src pathways (Boyle 2003). (BOYLE
DIAGRAM)
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Since RANK lacks intrinsic enzymatic activity in its intracellular domain, it
transduces signalmg through the recruitment and activation of cytoplasmio tumor
necrosis factor receptor-associated factors (TRAFs) (Asagiri 2006). The binding of
TRAFs to specific cytoplasmic domains within RANK is the key preliminary step in
RANK signaling (Hsu 1999). TRAF2, -5 and -6 have all been shown to bind to
RANK; however, only TRAF6 mutations result in osteopetrosis due to a loss of
osteoclast activity (Lomaga 1999).
The RANK signaling pathway has several levels of control that enhance or
dampen osteoclastogenesis and activation ddven by RANKL (Boyle 2003). in vitro
activation of osteoclast surface receptors for IL-I, c-F ms, TNF -a, PGE2 and

TOF-~

potentiate osteoclastogenesis, and can stimulate bone resorption in vivo (Boyle 2003).
Signaling through TRAF -6 by IL l-R and TNFR 1, and activation of these receptors
could have a synergistic effect on RANK-mediated TRAF6 activation (Mak 2002). It
has been reported that the activation of c-Fms and

TGF-~

up-regulates com.ponents of
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the pathway, including the levels of RANK on the cell surface, thereby impacting the
potency of the RANKL in this system (Arai 1999). Osteoprotegerin (OPG)
negatively controls the RANK signaling pathway in vitro and in vivo (Simonett
1977). Evidence exists for feedback mechanisms that switch off the RANK signaling
pathway once it is activated. Secretion of interferon-~ due to activation of
osteoclastogenesis by RANKL acts in an autocrine manner to downregulate the
expression of c-Fos, a critical factor involved in osteoclast development (Takayanagi
2002).
Receptor activator of NFK8 ligand (RANKL)

RANK and RANKL are two members of the TNF family that are primary
regulators of bone remodeling and are necessary for the development and activation
of osteoclasts. The rank! gene was cloned by four independent groups at the same
time (Anderson 1997) (Lacey 1998) (Wong 1997) (Yasuda 1998). This gene
encodes a molecule of 316 amino acids, and three RANK-L subunits which assemble
to form a trimeric molecule (Theill2002). Disruption of this gene in mice causes
severe osteopetrosis, tooth eruption impairment, and osteoclast absence (Kong 1999).
Osteoblast/stromal cells and primitive mesenchymal cells that surround the
cartilagionous anlagen, hypertrophied-chondrocytes and activated T cells express
RANKL which is a membrane bound factor. RANKL is made by T cells following
antigen-receptor stimulation (Thei112002). RANKL's discovery helped establish that
osteoblasts/stromal cells support osteoclast differentiation primarily by serving as a
source ofRANKL as well as M-CSF (Suda 1999). M-CSF and RANK bind to their
respective receptors, c-fms and RANK expressed on osteoclast precursors to
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stimulate formation of osteoclasts. M-CSF and RANKL have been shown in vitro to
be sufficient for osteoclastogenesis (Quinn 1998). RANKL also mediates activation
and survival of mature osteoclasts (Lacey 1998). Through investigation of the
RANKIRANKL system, many osteotropic hormones and cytokines have been
revealed that regulate osteoclast formation and function through modulating RANKL
expression by osteoblasts/stromal cells (Hofbauer 2000).
Molecules that regulate RANKL include PTH (Lee and Lorenzo, 1999), vitamin-

D3 (Miura et aI., 2002), TNF -u (Hofbauer et aI., I999b), glucocorticoids (Chung et al
200 I), PGE2 (Li 2002), interleukin-l and -11 (Hofbauer I999b), thyroid hormone
(Miura 2002), lipopolysaccharide (Kikuchi 2001), fibroblast growth factor-2 (FGF-2)
(Chikazu 2001), insulin like growth factor-I (lGF-I) (Rubin 2002),

TGF-~

and

BMP-2 (Theill 2002) and low gravity (Kanematsu 2002). T cell/dendritic
communications, dendritic cell survival, and lymph node organogenesis are also
regulated by RANK-L (Theill2002). Activated T cell production ofRANK-L can
regulate osteoclastogenesis and bone remodeling. RANK and RANK-L also have an
essential role in the formation of a lactating mammary gland during pregnancy
(Theill 2002).
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Osteoprotegerin (OPG)
Osteoprotegerin (OPO), homolgous to TNF receptor family members, is a
secreted protein which serves as a soluble decoy receptor to RANK-L and competes
with RANK for RANK-L binding making it an in vitro inhibitor of osteoclast
maturation and activation (Simonet 1997). OPG is expressed in the stromal cell line
and human bone marrow stromal cells, is down regulated by bone resorbing factors
vitamin D3, prostaglandin E2 (PGE2) and glucocorticoids, and upregulated by calcium
ions and TGF-p (Brandstrom 1998). Osteopetrosis results from the overexpression of
OPG in transgenic mice (Simonet 1997).
Developmental regulation, activation of osteoclasts and bone metabolism
experiments by different groups show that there is a balance between RANK-LRANK signaling and biologically active levels of OPG (Theill 2002). This complex
system of bone remodeling regulated by osteoclasts appears to be controlled by these
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three molecules (Theill 2002). However, osteoclast formation and activation is also
controlled by genes, hormones and cytokines.

TABLE 1 Molecules that regulate RANK-L and OPG levels
IRANKL
Hormones
Increased
Vitamin-D3
Increased
PTH
PTHrP
Increased
No change
Estradiol
Cytokines
Increased
Tf\lF-a
IL-1
Increased
Increased
IL-6
Increased
IL-11
Increased
!L-17
Growth factors
Decreased
TGF-~
BMP-2
n.t.
Others
Increased
Prostaglandin E2
Increased
Glucocorticoid
CD40L
Increased

IOPG

I

Increased
Decreased
Decreased
Increased
Increased
Increased
n.t.
n.t.
n.t.
Increased
Increased
Decreased
Decreased
n.t.

-

Theill, et al. Annu Rev. hnmunol 2002

Tumor Necrosis Factor Receptor-Associated Factors (TRAF's)
The TRAF family consists of seven distinct proteins and serve as cytoplasmic
adapters that can interact directly with the intracellular domains of cell surface
receptors, such as the TNF receptor family, and mediate signaling (Asagiri 2006).
TRAF-6 is the essential adaptor required for RANK-associated signaling and is the
only member of the Toll/IL-lR family to have interaction with lL-lR associated
kinase (lRAK). It binds to the membrane-distal domain of RANK's cytoplasmic tail
(Cao 1996). As mentioned earlier, TRAF-2 and -5 have also been shown to bind to
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RANK; however, osteopetrosis due to a loss of osteoclast activity, only results when
TRAF-6 is blocked (Lomaga 1999). TRAF-6 acts as a key adaptor to assemble
signaling proteins that direct osteoclast-specific gene expression leading to
differentiation and activation. The activation of transcription factors NF -K~ and
activator protein-] (AP-l) are the two most closely studied pathways involved with
TRAF -6 since their activities are rapidly induced following ligand-binding (Boyle
2003).
One of the most important and earliest pathways activated by RANK is NF-K~.
This pathway is relevant for RANKL-RANK regulated osteoclast development and
osteoclast function in mice and humans (Doffinger 2001). Although TRAF6 is
critical for the RANK-induced activation ofNF-KB, it is unlikely that NF-KS is the
only downstream molecule mediating the complex functions ofTRAF6 (Asagiri
2006). However, among the molecules immediately activated by TRAF6, genetic
evidence supports the essential role ofNF-KB, but not that of other molecules, such as
mitogen-activated protein kinases (MAPKs), in osteoclastogenesis (Asagiri 2006).
NF-KS activation depends on two pathways: the classical and alternative (Asagiri
2006). The classical pathway involves the IKK complex as described earlier which
involves activation of the inhibitor of the KS (IKS) kinase (IKK) complex that
phosphorylates the IKBs arid targets them for ubiquitin-dependent degradation
(Asagiri 2006). The alternative pathway is responsible for activation of the p52:RelB
dimers, which are generated by the processing of the c)10plasmic plOO:RelB complex
(Asagiri 2006).
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Nuclear factor kappa beta

Nuclear factor kappa beta

(NFK~)

is a collective name for a group of transcription

factors that are necessary for innate and adaptive immunity. They are members of the
ReI family of transcriptional activator proteins and are found in the cytoplasm of most
cells (Thanos 1995). They were first described in 1986 as a nuclear factor in B cells
that bound a site in the immunoglobulin K enhancer (Sen 1986). It was soon shown
that their activation in other cells occurred by exposure to stimuli such as phorbol
esters (Sen 1986) and in the following years, functional binding sites for NF -K~ were
found in the promoters of many genes (Baldwin 1996).

NF-K~

binding sites usually

act as transcriptional regulatory factors that induce a wide variety of genes involved
in immune function, inflammatory response, cell adhesion and growth control
(Baldwin 1996) such as pro-inflammatory cytokines TNF -a, interleukin 1 and-6,
chemokines, RANTES (regulated upon activation, normal T-cell expressed and
secreted) and vascular cell adhesion molecule-1 (VCAM-1) and E-selectin (Zhang
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2001). Microbiocidal effector molecules and enzymes that create intermediates such
are nitric oxide are also induced by NF-K~ (Zhang 2001). T and B cell activation eLi
2002) and regulation of peripheral lymphoid organogenesis is also induced by NF-K~
(Weih 2003). Its activation is not only limited to mediators of immune function,
other stimuli such as UV irradiation, growth factors and viral infection activate NF-a~
(Baldwin 1996).
There are five NF -K~ proteins expressed in mammals which are made up of
complexes of ReI family polypeptides and are divided into two different groups
based on structure, function and mode of synthesis (Siebenlist 1994)). Subunits p50
(NF-K~I)

and p52

(NF-K~2)

comprise the first group and are synthesized as

precursor proteins (Thanos 1995). They become active when they are processed
proteolytic ally (Xiao 2001). The second group which are not synthesized as
precursors, include p65 (ReI A), RelB, and c-Rel (Beinke 2003). Rel-A and c-Rel
can activate transcription from target gene

NF-K~

binding sites and Rel-B can

complex with p50 or p52 to function as an NF-K~ activator (Beinke 2003).
RelBlRelA complexes cannot bind DNA so they are inhibitory. p50 and p52 subunits
can only promote transcription when heterodimerized with a transactivated ReI
subunit. (Beinke 2003)
Due to a defect in osteoclast differentiation, mice lacking NF-K~1 and NFK~2
develop osteopetrosis which suggests a redundant role

ofNF-K~1

and NF-K~2

(Iotsova 1997). This suggests that early stage arrestment of osteoclast differentiation
is attributed to the complete lack of osteoclasts in these mice. NF -KJ31 and NFK~2
are essential for RANK -expressing osteoclast precursors to differentiate, in response
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to RANK and other osteoclastogenic cytokines, into TRAP+ osteoclasts; however,
they are not required for formation of RANK -expressing osteoclast progenitors (Xing
2002).

NF-K8 Activation Pathway
NF-K~

Inhibitors

dimers are inactive and sequestered in the cytoplasm of unstimulated cells.
ofNF-K~

(IkWs) are the proteins responsible for keeping NF-K~ dimers in

a cytoplasmic quiescent state (Verma 1995). Stimuli such as LPS, TNF -a and IL-l
cause a signaling cascade which likely leads to activation of multiple upstream
kinases and an increase in the activity of the

IK~

kinases (IKK) (Ghosh 2002).

Specific serines within the IkW s are phosphorylated by the IKK complex which
results in their degradation mediated by proteasomes. With the degradation of the
Ik~' s,

the NF -K~ dimers move to the nucleus to activate target genes (Stancovski

1997).
Studies indicate that phosphatidylinositol 3-kinase (P13K) is a dO\\'llstream
effector involved in liberating NF-K~ from

IK~

(Reddy 1997). It consists of a

catalytic (p 11 0) and regulatory (p8S) subunits which activate lipid substrates at the
cell membrane that act as secondary messengers (Sizemore 1999). LPS stimulation of
monocytes/macrophages activates the P13K pathway (Lee 2000). It is unclear how
P13K and its downstream effectors feed into a signal transduction cascade that leads
to activation ofNF -K~ ( (Bergmann 1998).
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Current studies demonstrate that LPS stimulation of monocytes leads to an
activation of the P13K-Akt pathway, which inactivates MAPK kinase pathways (ERK
~Iz,

p38 and JNK) and the the NF-K~ pathway (Guha). Blockage of these pathways

with the use of inhibitors, such as LY294002, limits the activation of the transcription
factors NF -K~, and AP-1 which regulated TNF -a gene expression. The PI3K-Akt
pathway is a control mechanism to limit the expression of TNF -a in LPS stimulated
monocytes which only enables transient expression of these inflammatory mediators
(Guha 2002)
Mitogen-activated protein kinases (MAPKs)
Cell-surface receptors are connected to critical regulatory targets within cells via
mitogen-activated protein kinases, which are evolutionary conserved enzymes (Chang
2001). Thrr major subfamilies of MAP kinases have been identified: extracellular
signal regulated kinases (ERKs), JNKs and p38 MAP kinases. Peptide growth factors
and phorbol esters preferentially activate ERKs, while cellular stresses, such as
hyperosmolarity or reactive oxygen species, potently activate JNKs and p38MAP
kinases (Iwasaki 1999). A three-tiered cascade regulates their activity and is
composed of a MAPK, MAPK kinase (MAPKK, MKK, or MEK) and a MAPKK
kinase (MAPKKK, or MEKK) (English 1999). Even though they are distinct in
their activation, there is considerable cooperation between these kinases and many
substrates are shared between pathways (Cobb 2000). A wide spectrum of cell
functions are influenced by this family ofkinases including proliferation (Pages
1993), apoptosis (Cross 2000), cytokine biosynthesis (Baldassare 1999), and
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cytoskeletal reorganization (Landry 1995). They control cell survival and adaptation
by responding to chemical and physical stresses and have been shown in vitro to play
an important role in osteoclastogenesis, but not yet in vivo (Asagiri 2006). They are
all highly conserved serine-threonine kinases that are activated by upstream MAPK
kinases through a Thr-Xxx-Tyr phosphorylation motif (Martin-Blanco 2000). Studies
have shown that growth factors, mitogenic stimuli and tumor promoters in general,
activate the ERK

~

pathway (Cobb 1999). The p38 and SAP/JNK pathways are

stimulated by environmental stress and inflammatory cytokines (Zu 1998). The
activation of the numerous transcription factors which function to stimulate the
synthesis of various inflammatory proteins, including the c)10kines T"N"'F -11,

IL-1~,

and IL-6, is through phosphorylation from MAPKs. The activation of the MAPKs by
LPS is initiated by a surprising number of pathways and likely reflects the different
cell types used in the various studies (primary cells or cell lines, human or mouse
cells, peritoneal or alveolar macrophages, etc.) (Schorey 2003). They are also
involved in the activation of components of AP-l, thereby possibly modulating its
activity during osteoclatogenesis. However, the molecular mechanisms as to how
they function are not understood well (Chang 2001). Some of them have been shown
to be activated dmvnstream of RANK. It has been suggested that p38 is involved in
osteoclast formation due to the effects ofp38 inhibitor placed on RA W264.7 cells
(Matsumoto 2000) and it has been shown to be involved with the induction ofthe
cathepsin K gene (Matsumoto 2004). RANKL also activated the ERKl/2 kinases;
however, osteoclastogenesis is potentiated when ERK activity is inhibited with a
selective MEK inhibitor, PD98059, which suggests that the ERK pathway negatively
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regulates osteoc1astogenesis (Hotokezaka 2002). PD98059 is a potent and selective
cell permeable inhibitor of MAP kinase. It blocks the activation of MEK, thereby
inhibiting the phosphorylation and the activation of MAP kinase and is invaluable in
helping elucidating the role of the MAPK cascade in a variety of biological systems.
It has also been suggested that ERK is involved in osteoclast survival (Miyazaki

2000). Studies have also shown that MEK inhibitors cause a decrease of
phosphorylated ERK and either suppress, or do not affect differentiation into
osteoclasts from bone marrow cells (Lee 2002)
The p38 MAPK family is a group of 38 kDa intracellular signal transduction
proteins which regulate gene expression in response to various extracellular stimuli
like tumor necoris factor-a and interleukin-l (Han 1994)and are predominantly
activated through phosphorylation by upstream MAPK kinase 6 MKK6 (Boyle
2003). P38 is phosphorylated in response to RANKL, IL-l, TNF-a and LPS in bone
marrow macrophages (Matsumoto 2000) which results in the downstream activation
ofthe transcriptional regulator mi/Mitf, which controls the expression of the genes
encoding TRAP and Cathepsin K, which are required by the mature osteoclast (Boyle
2003). Their physiological functions have been investigated through the use of
specific inhibitors such as SB202190, a pyridinyl imidazole, which competes with
ATP for the same binding site on the p38 kinase (Nemoto 1998); therefore, inhibiting
the differentiation of bone marrow cells into osteoclasts by interfering with the
RANKL-induced p38 MAP kinase activity (Matsumoto 2000).
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Macrophage Colony Stimulating Factor (M-CSF)
Entrance of mononuclear cells into the early preosteoclast pathway, after
commitment to the osteoclast lineage, is in response to macrophage colonystimulating factor (M-CSF). Proliferation, differentiation and survival of
hematopoietic cells in the monocytic lineage require M-CSF (Suda 1992).
Mesenchymal cells such as fibroblasts, osteoblasts and endothelial cells, as well as
activated macrophages, synthesize this growth factor (Felix 1994). There is a
macrophage deficiency and a lack of osteoclasts with the absence of a functional MCSF in the op/op mouse (Kodama 1993). An injection ofM-CSF can restore these
deficiencies (Kodama 1993). Experimental evidence shows that M-CSF is not
essential for the early stages of osteoclast development because the differentiation
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and proliferation of osteoclast progenitors from inoculated stem cells can be
supported by op/op marrow stromal cells (Lee 1994),
A variety of intracellular signals are activated which recruit adapter proteins and
cytosolic kinases when M-CSF binds to its receptor, c-Fms. The cytoplasmic tail of
c-Fms contain tyrosines 559 and 807 which play distinct roles in osteoclast
differentiation and function (Zhao 2007). M-CSF receptor expression changes
modulate the final lineage selection of the pluripotent monoblastic progenitor (Fan
1997). A direct respone to RANKL and interleukins require M-CSF induced genes.
RANK and other RANKlNFK~ pathway components have been shown to be induced
by M-CSF, thus providing a molecular explanation for the synergy ofM-CSF and
RANKL (Cappellen 2002) M-CSF has also been shown to induce interleukins,
interferons, and their receptors (Capellen 2002). Inhibition of apoptosis of osteoclast
precursors is also mediated by M -CSF (Woo 2002).

Activator protein-l (AP-I)
AP-l is a transcription factor comprised of a variety of dimers of members of the
Fos, Jun and ATF families of proteins (Angel 1991). Ligands binding to cell-surface
receptors, RANK for osteoclasts and Toll-like receptors (TLRs) for mononuclear
phagocytes, lead to differentiation of the common precursors into either bone or
immune lineages through expression of specific target genes that contain AP-l
binding sites (Zhao 2007).

NF-K~

and AP-l are both activated by RANK and TLRs.

C-Fos and Fra-l are members of this family, and c-Fos inactivation in mice results in
arrested osteoclastogenesis and elevated numbers of marrow macrophages
(Grigoriadis 1994). The introduction of c-Fos protein can rescue osteoclast

35

differentiation (Wang 1992). Therefore, c-Fos is essential for the commitment of
hematopoietic precursors to become osteoclasts instead of mature macrophages
(Tietelbaum 2000).
A redundant role is played by the Jun family of proteins, partners of the Fos family
of proteins, in osteoclastogenesis. In knock-out mice, a deficiency in JunB or c-Jun
leads to a sizable decrease in osteoclast formation but not a complete blockade,
suggesting that during osteoclastogenesis, members of the Jun family substitute for
each other (Arai 1999). AP-l has a critical role in osteoclast differentiation and is
also involved in numerous cell processes including: cell differentiation, proliferation,
apoptosis and oncogenic transformation. Its activity is regulated through interactions
with transcriptional and post-transcriptional regulators and by upstream kinases that
link it to different signal transduction pathways (Jochum 2001). Since it is at the end
of several signal transduction cascades, it is considered a stress responsive
transcription factor complex (Masuo 2003).

Nuclear factor of activated T-cell cytoplasmic (NFATc)
Nuclear factor of activated T-cell cytoplasmic (NFATcl) was shown to be
strongly induced by RANKL in a genome-wide search fer the RANKL-inducible
genes required specifically for the terminal differentiation of osteoclasts (Ishida
2002). There are four members of this transcription factor family (NFATcl through
NFATc4) which were originally identified in T-cells (Zhao 2007). NFATc1 has been
referred to as the master transcription factor for osteoclastogenesis (Kim 2005). The
immune, cardiovascular and skeletal systems are all regulated by them to some
degree (Crabtree 2002). Calcineurin, a specific phosphatase that is activated by

36

calciurnicalmodulin signaling, mediates the activation of the NFAT family. NFATc1
is controlled by the phosphatase calcineurin, which plays a critical role in the
coupling of calcium signals with cellular responses (Klee 1998). Once activated by
an increase of the intracellular calcium concentration, calcineurin induces the
translocation of NF ATc 1 into the nucleus where it activates the transcription of
specific target genes (Kim 2005). RANKL-induced osteoclastogenesis and NFATc1
induction are strongly inhibited by the calcineruin inhibitor FK506. This shows the
importance of calcium signaling during osteoclast difTerentiation (Takayanagi 2002).
FK506 inhibits immune function by blocking the enzyme activity of calcineurin
(Fukunaga 2004), Complexes are formed when the drug binds with FK506-binding
protein (FKBP) which in turn reduces the expression of cytokines (Uu 1991).
It has been suggested that NF ATc 1 is one of the key target genes

ofNF-K~

in the

early phase of osteoclastogenesis since its induction was impaired in TRAF6 negative
cells (Takayanagi 2002), through the use of an NF-K~ inhibitor (Takatsuma 2005) and
in p50/p52 deficent cells (Li 2004). It has also been shown that NF-K~ is recruited to
the NF A Tc 1 promoter immediately after RANKL stimulation (Asagiri 20056).
NF ATc2 is another preexisting molecule that is recruited to the NF ATc 1 promoter
within minutes ofRANKL stimulation and at the same time as NF-KB (Asagiri 2006).
However, the loss ofNFATc2 might be compensated for by other NFATs, since
NF A Tc2 deficient mice have no defects in osteoclastogenesis ( (Asagiri 2005).
Promoter analyses shows that NF ATc 1 regulates a number of osteoclast-specific
genes such as TRAP (Kim 2005), calcitonin receptor (Anusaksathien 2001), cathepsin
K (Kim 2005) and

~3

integrins (Crotti 2006); however, the critical binding sites have
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not been identified fully. It is not understood how the target genes ofNF ATc 1
promote the differentiation process (Asagiri 2006). In the context of transcriptional
control by NF A Tc 1, the process of osteoclast differentiation can be divided into three
stages. First, the recruitment ofTRAF6 due to RANK-RANKL interaction leads to
the activation of downstream molecules such as NF-K~. The NFATcl promoter
recruits NFATc2 in the early phase also. The initiation of NFATcl occurs through
the cooperation ofNFK~ and NFATc2. Secondly, NFATcl, stimulated by calcium
signaling, is activated and binds to its own promoter which leads to the
autoamplification of NFATcl. AP-l containing c-fos is essential for this to occur.
There is selective recruitment ofNFATcl, induced by RANKL, to the promoter of

NFATcl , but not to that of NFATc2. Lastly, a transcriptional complex containing
NFATc1 and cooperators such as as AP-I, PU.l and micropthalmia-associated
transcription factor (MITF) activate a number of osteoclast-specific genes such as
cathepsin K, TRAP, calcitonin receptor and OSCAR (Asagiri 2006).

(i) Initial induction of
NFATC1

(ii) Autoarnpfification Qf
NFATcl

(iii) Induction of osteoclastspecific genes

Asagiri , Bone 2006.
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Costimulatorv signals for RANK

NFATcl also regulates the osteoclast-specific immunoreceptor osteoclastassociated receptor (OSCAR) (Kim 2005). OSCAR is an immunoglobulin-like
receptor expressed by osteoclasts. It is involved in the cell to cell interaction between
osteoblasts and osteoclasts (Kim 2002) and has been shown to associate \"rith an
adaptor molecule, FcRy (Koga 2004) which contains an immunoreceptor tyrosinebased activation motif (ITAM), that is essential for the activation of calcium
signaling in immune cells (Reth 1989). DAP12 is another ITAM-harboring adaptor,
and has been shown to have involvement in the formation and function of osteoclasis
(Kaifu 2003). Due to the differentiation blockade of osteoclasts, mice deficient in
FcRy and DAP12 exhibit severe osteopetrosis, demonstrating that immunoglobulinlike receptors, which include OSCAR, triggering receptor expressed in myeloid cells
(TREM)-2, signal-regulatory protein (SIRP) Betal, and paired immunoglobulin-like
receptor (PIR)-A associated with FcRy and DAP12 are essential for
osteoclastogenesis (Koga 2004). However, the precise function and ligands of these
receptors is not

knOWTI.

ITAM-mediated signals, costimulatory signals for RANK,

work with RANK to stimulate calcium signaling through ITAM phosphorylation
resulting in the activation of Syk family kinase and phospholipase Cy (PLCy). The
immunoglobulin-like receptors associated with FcRy and DAP12 have been
identified as essential RANK partners during osteoclastogenesis (Baron 2004),
however, how RANK can specifically induce osteoclastogenesis in cooperation with
IT AM signaling, is not fully understood (Asagiri 2006).
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Micropthalmia-associated transcription factor (MtiO
The basic/belix-Ioop-helix/leucine zipper (b-HLH-ZIP) transcription factor
subfamily has microphthalmia-associated transcription factor (Mitf), Tfe3, Tfeb, and
Tfec as members (Zhao 2007). The proper development of osteoclasts, melanocytes,
retinal pigment epithelial cells, mast cells and natural killer cells require Mitf.
Defective osteoclast development with osteopetrosis is found with Mitf mutations
(Hershey 2004). There is induction of the osteoclast-specific marker of the TRAP
gene when MITF interacts with either PU.1 or PU.1 interacting protein (Partington
2004). The OSCAR gene is activated by PU.1 and MITF transcription factors also.
RANKL targets MITF in the osteoclast signaling pathway, and MITF
phosphorylation causes an increase in ~C-specific gene expression (Mansky 20(2).

There are four related genes in the Myc family which are are key regulators of cell
proliferation and contribute to the genesis of many human tumors: c-Myc, N-Myc, LMyc, and S-Myc (Adhikary 2005). RANKL-induced osteoclast-like cells show
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upregualtion of c-Myc, with absence of c-Myc in undifferentiated cells (Zhao 2007).
RANKL-induced osteoclast formation was blocked in dominant negative Myc in raw
264.7 cells; therefore, expression of c-Myc is required for RANKL-induced
osteoclastogenesis and is a downstream target of RANKL (Battaglino 2002).

Src
Deletion of the gene encoding c-Src, which is a member of a family of nine
NRTKs that associate with the cytoplasmic surface of cellular membranes, results in
osteopetrosis, and is a result of the inablility of the mature osteoclast to resorb bone
(Brown 1996).

Tumor Necrosis Factor (TNF)
In the eighteenth century, shrinkage of tumors in some cancer patients who were
exposed to severe bacterial infections, led to the belief that some biological factor
mediated this tumor necrotic activity (Coley 1893). In 1968, lymphotoxin, a soluble
protein produced by T -lymphocytes was discovered (Granger 1968). Experiments
demonstrated in 1975 that subsequent to stimulation of their reticuloendothelial
system and lipopolysaccharide challenge, a protein, termed "Tumor Necrosis Factor"
(TNF), was released into the circulation of animals (Carswell 1975). It was named as
such because this protein was shown to cause rapid necrotic regression of certain
forms of tumors. However, not all tumors were susceptible to it and any therapeutic
potential was diminished by its systemic toxicity at effective concentrations (Idriss
2000).
TNF-a and lymphotoxin (TNFbeta and LT-alpha) both define two structurally and
functionally related proteins (Aggarwal 1991). Since their isolation and cloning in
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1984 from activated macrophages and T cells, (Gray 1984), the TNF family has been
expanded to include nineteen members (Locksley 2001). TNF-a has been established
as a major mediator of inflammation; however, other family members regulate a
variety of cellul£l.r functions such as cell differentiation, function, survival and
apoptosis (Gaur 2003).
TNF Receptors
TNF receptors (TNFR) are found on almost all cell types except for
erythrocytes and unstimulated T lymphocytes. There are twenty-nine known
members which are usually type I transmembrane proteins; however, a few TNFR
members are secreted soluble proteins. (Feng 2005). No correlation has been found
between receptor density and the magnitude or direction of the TNF -induced response
(Beyaert).
Many membrane bound receptors, including the TNF-a receptors,TNFRl and
TNFR2, form what is kJlo\vn as the TNF receptor superfamily (Bazan 1993). Since
they lack enzyme activity in their intracellular domains, TNFR family members
transduce signaling through the recruitment of adapter proteins, primarily death
domain-containing proteins and members of the TRAF family.
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TNF-a and its receptors TNFRI and TNFR2

TNF-a is a cytokine that promotes the inflammatory response. It is mainly
produced by macrophages but also by endothelial cells, fibroblasts, mast cells and
neuronal tissue, TNF -a has varied biological functions with a somewhat complex
mechanism of action, Its intracellular signaling pathways have been delineated and
its target genes that control its function have been identified (Beutler 1999),

It

confers resistance to certain infections but causes pathological complications in other
instances (Fiers 1991). Lack of resistance to leishmania and failure to form splenic
germinal centres were shown in mutant phenotype of knock-out mice that lacked the
gene for TNF-a (Goldfield 1996). The important role ofTNF-a in conferring
immunity and a proper inflammatory response was shown with TNFR knockout mice
that, when challenged with bacterial endotoxins, displayed an increased susceptibility
to microbial infection and a suppressed inflammatory response (Acton 1996).
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Immunostimulation, resistance to infection agents, resistance to tumors (Aggarwal
1991), sleep regulation (Krueger 1998) and embryonic development (Wride 1995) are
amongst the processes that TNF-a plays a role in. However, due to TNF-a
circulation, parasitic, bacterial and viral infections become more pathogenic or fatal
(Fiers 1991).
The TNF-a gene is a single copy gene on the short arm of human chromosome 6
and murine chromosome 17 and is preceded by TNF-~ (Spriggs 1992). TNF-a exists
in a membrane bound an a soluble form, with each possibly carrying out a distinct
physiological role (BeyaertI994). It is first produced as type II membrane protein,
unlike TNF -p which is secreted (Idriss 2000) and exists in a more diverse range of
cells than TNF-p. It is produced in a variety of hematopoietic and non-hematopoietic
cells, both normal and malignant which include macrophages, CD4+ and CDS+ Tlymphocytes, B-lymphocytes, NK cells, neutrophils, astrocytes, endothelial cells,
smooth muscle cells and tumor cell lines of non-hematopoietic origin (Vilcek 1991).
TNF-a exerts its function via two receptors, TNFRI (also known as p55), which
contains a death domain (Himmler 1990) and TNFR2 (also known as p7S) which
lacks a death domain (Gray 1990). TNFR-l is widely distributed on cells such as
fibroblasts and epithelial cells, and TNFR-2 is mainly confined to cells of
hematopoietic origin (Armitage 1994). As discussed earlier, RANKL and RANK are
essential for osteoclastogenesis since the mice deficient for either RANKL or RANK
completely lack osteoclasts (Li 2000). In contrast, the mice lacking ThTF-a or its
receptors do not exhibit any bone defects (Marino 1997) Both TNFRI and TNFR2
are implicated in osteoclast formation and function. In pathological
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circumstances,TNFR1 positively regulates osteoclast formation and function (AbuAmer 2000), in contrast, TNFR2 exerts an inhibitory effect on osteoclast formation
and function (Abu-Amer 2000). Signaling pathways activated by TNFR1 and
TNFR2 have been intensively investigated in a variety of other cell types. TNFR1
receptor binding leads to activation of factors such as capase 8 and apoptosis. The
second group which includes 'fJ\TFR2, CD40 or CD30 bind TRAFS, which are
molecular adapters that link these surface receptors to downstream signaling which
activate JNK, SAPK and NFa~ (Locksley 2001). It has been shown that TRAF
binding domains, particularly TRAF6, are functionally important for the RANKdependent induction ofNF-K~ and c-Jun NH2-terminal kinase (JNK) activities.
When the TRAF6 interaction domain was deleted, NF-K~ signaling mediated by
RANK was completely inhibited (Damay 1998). However, the precise signaling
cascades leading to the activation of these pathways have not been functionally
established in osteoclast precursor/osteoclasts and are based on studies involving cells
other than osteoclast precursors/osteoclasts (Feng 2005). Further studies are needed
to evaluate whether these signaling cascades are used to activate NF-K~, JNK, p38,
ERK, and Akt in osteoclast precursors/osteoclasts (Feng 2005).
It has also been shown that TNF -a can modulate osteoclast formation and
function by enhancing the expression ofRANKL by osteoblasts and stromal cells
(Hofbauer 1999) and is mediated via TNFR1 (Abu-Amer 2004). However, the
molecular mechanism by which TNF -a regulates RANKL gene expression in
osteoblasts/stromal cells is still not known.
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Tl~F-a

also stimulates M-CSF production by murine or human stromal cells

(Srivastava 2001). TNF-a is among the most potent of the osteoclastogenic cytokines
produced during inflammation. Not only has it been implicated in the pathogenesis of
conditions which include rheumatoid arthritis, orthopedic implant loosening, and
other forms of chronic inflammatory osteolysis (Birkedal-Hansen 1993), it also
mediates LPS-stimulated osteoclastogenesis via its p55 receptor, through a
mechanism involving activation ofNF-KB (Abu-Amer 1997). A topic of
considerable debate has been whether TNF -a promotes osteoclast formation
independently of RANK signaling. It has been demonstrated by two independent
groups that TNF-a promotes osteoclast formation in vitro despite RANK signaling
blockade (Azuma 2000, Kobayashi 2000); however, others report that "permissive"
levels ofRANKL are required for TNF-alpha-induced osteoclastogenesis (Lam
2000).
The purpose of this study was four-fold: to determine ifLPS shares the same
pathway with RANK for osteoclastogenesis, to determine whether TNF -a can
stimulate osteoclast formation directly, to examine the effect ofLPS on TNF-a
release during osteoclast formation and to examine the effect of blocking the TNF-Oreceptor.
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Material and Methods

Reagents

All media components were purchased from GIBCO. RANKL and TNFa, TNF-a
ELISA was obtained from R&D Systems. E. Coli LPS was obtained from Sigma.
SB202190, PD98059, LY294002 and FK506 were obtained from Calbiochem.
Preparation of osteoclasts

Osteoclast-like cells (OCL) were differentiated from RAW 264.7 cells, a mouse
hematopoietic cell line (American Type Culture collection, ,Rockville, MD).

For

morphological examination, RAW 264.7 cells were plated at a density of 40,000
cells/well in 24 well plates in Alpha modified Eagle medium with 10% fetal bovine
serum (Invitrogen, Carlsbad, California). The cells were incubated at 37°C in a
humidified atmosphere containing 5% CO2 ,
TRAP Assav
Tartrate resistant acid phosphatase (TRAP) is a marker enzyme specific for
osteoclasts. At 96 h of culture, cells were fixed with 2% paraformaldehyde, washed
with phosphate buffered saline, and treated for 20 minutes with 0.2% Triton X-IOO
solution to permeabilize cell membranes. Cytochemical staining of tartrate-resistant
acid phosphatase (TRAP)-positive cells was performed.

TRAP-positive cells

appeared dark red. Only TRAP-positive cells with more than 3 nuclei were counted.
The values are expressed as means ± SE of triplicate cultures.
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ELISA
Concentrations ofTNFa in culture supernatants were determined by ELISA in
triplicate with commercial ELISA Duo systems (R&D systems), according to the
respective manufactures' instructions. For each sample and assay, the mean of the
triplicate measurement were calculated.

Statistical Analvsis
Data were expressed as mean values ± SD. Statistical significance of differences was
determined by one way ANOVA and followed by post hoc test (Fisher'S protected
least significant difference). Differences were considered statistically significant at

p<O.05.
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Results
Each group contained three wells and was run in triplicate. Three investigators
counted the cells.

LPS/RANKL Pathway
In order to investigate if LPS and RANKL share a common pathway for activation of
osteoclastogenesis, various receptor or pathway inhibitors were used. In the graph
below, the upper portion represents the RANKL treated group and the lower portion
represents the LPS treated group. When cells treated with RANKL were cultured
with OPO, which is a soluble inhibitory peptide that binds to RANKL, thereby
reducing its availability and blocking RANK signaling, there was almost complete
inhibition of osteoclast formation. However, when this group was cultured with an
antibody to the LPS receptor, TLR4, no effect is seen. Conversely, when the LPS
group was cultured with OPG, there was osteoclast formation, however, with use of
anti-TLR4, there is a reduction in osteoclast formation.
RANKL

325 osteoclasts

RANKL + OPO

560steoclasts

RANKL + Anti-TLR4 - 301 osteoclasts

LPS

225 osteoclasts

LPS + OPG

2430steoclasts

LPS + Anti-TLR4 -- 85 osteoclasts

As seen in the following graphs, there were dramatic reductions in osteoclast
formation in the LPS and RANKL group when pathway inhibitors of p38 MAPK,
PI3K or calcineurinINF AT pathways were used; however, there was no inhibition
when an inhibitor for the MEKK pathway was used.
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RANKL treated group

LPS Treated group

Control - 285 osteoclasts
MAPK inhibitor SB202190

320osteoclasts
62 osteoclasts

84 osteoclasts

MEKK inhibitor PD98059 - 395 osteoclasts

440 osteoclasts

P13K inhibitor LY294002

40osteoclasts

NF AT2/Calcineurin inhibito FK506 - 10 osteoclasts

64 osteoclasts
20 osteoclasts

TNF-(1. stimulation of osteoclastogenesis
Osteoclast precursors were pretreated with RANKL for 24 hours. RANKL was
removed and TNF -a was supplemented at doses of 0.1 ng/ml, 10 ng/ml and 50 ng/ml
for an additional 72 hours. In addition, two sets of cell groups were treated with 50
ng/ml of TI~F only or RANKL only for 24 hours. The cells that were treated with
only TNF-a or RANKL for only 24 hours had no osteoclast formation. With 10
ng/ml and 50 ng/ml ofTNF-a, as shown in the graph below, there was marked
formation of TRAP+ multinucleated cells in the culture. This indicates that TNF-a
dose-dependently stimulates osteoclast formation if previously exposed to RANKL.
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LPS-stimulated release of TNF-alpha

The effect of LPS on TNF -u release during osteoclast fonnation was examined by
ELISA.

• ELISA results
Group Treatment

'I 'NF-a Release

\

No treatment

Not detectable

I)

100 ng/ ml LPS

23.49± 0.98 ng/ml

(

50 ng/ ml RAN KL (24
h)+ 100 ng/ml LPS (72h)

4.32 ± 0.12 ng/ml

52

Group A cells which received no treatment, had no TNF-a release detected by
ELISA. Group B cells which received 100 ng/ml of LPS had a TNF -a release of
23.49 ng/ml detected. Group C cells which received 50 ng/ml of RANKL which was
then removed, and then were treated with 100 ng/ml ofLPS, had TNF-a release of
4.32 ng/ml detected by ELISA.

Blocking the TNF-(1 receptor
The effect of blocking the TNF-a receptor was examined .. Below is a summary of
this treatment.

On the left panel above are the cells that received RANKL for the first 24 hours and
were then treated with TNF-a, additional RANKL or LPS. On the right panel are the
cells that were treated with the TNF-a blocker. Osteoclast formation due to TNF-a
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stimulation was completely abolished. Osteoclast formation due to RANKL was
unaffected, and osteoclast formation due to LPS decreased by 60%.
Discussion
Chronic inflammation of bone or periosseous tissues by Gram-negative bacteria as
seen in endodontic infection causes osteolysis due to osteoclastic bone resorption, a
process driven by host inflammatory responses. There is also a causative role of
lipopolysaccharide-producing bacteria in the pathogenesis of apical periodontitis
(Sundqvist 1976). Periapical bone destruction and apical periodontitis occur when
the pulp is infected with certain anaerobic Gram-negative species since the necrotic
pulp is insufficient by itself to cause these conditions (Sundqvist 1976). Prolonged
or excessive release of cytokines plays a central role in the pathogenesis of
inflammatory bone destruction. One of the most potent osteoclastogenic cytokines
produced in inflammation is TNF-a (Lam 2000). It has been shown to be involved in
the pathogenesis of conditions including rheumatoid arthritis, orthopedic implant
loosening and other forms of chronic inflammatory osteolysis (Nair 1996).
Lipopolysaccharide-stimulated osteoc1astogenesis via its p55 (TNFRl) receptor
which involves activation ofNF-kP is mediated by TNF-a (Abu-Amer 1997).
The host defense response to LPS includes expression of a large variety of proinflammatory cytokines which include TNF -11, interleukin-l p, IL-6, interferon
gamma, IL-12, IFN inducible protein-lO, chemotactic cytokines, like monocyte
chemotactic protein-5, IL-8, MIP-lalpha and MIP-2,andprostaglandin E2 (Madianos
2005). The mechanism of action ofLPS is not fully understood; however, it
stimulates a variety of mechanisms during inflammation. LPS induces RANKL
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expression in osteoblasts, activated T -cells, synovial fibroblasts and bone marrow
stromal cells. It has been shown that LPS is able to induce osteoclast formation after
RAW 264.7 cells were primed with RANKL (Jiang 2003). LPS can also induce the
activation ofNF-kB and upregulate the expression levels ofTNF-alpha (Jiang 2003).
It is known that LPS primes polymorphonuclear leukocytes (PMNs) to release

reactive oxygen radicals and causes an increase in the surface expression and activity
of neutrophi1 adhesion molecules (Lynn 1992). It is also known that the adherence
ofPMN's and monocytes directly to endothelium is promoted by LPS (Lynn 1992).
It has also been sho'WTI that after three to seven months of experimentally applied

bacterial LPS into the root canals of monkeys, the periapical tissues showed signs of
resorptive bone loss inflammatory reactions (Dahlen 1981). This provides strong
evidence that LPS is essential to the formation of periapical lesions.
The first host protein involved in LPS recognition is LPS-binding protein, which
complexes with the lipid A moiety ofLPS. This complex allows LPS to dock at the
LPS receptor complex by forming a complex with CDI4. This allows LPS to be
transferred to the LPS receptor complex composed of TLR4 ,and MD-2 (PalssonMcDermott 2004). It was initially thought that CD14 was the long sought after
receptor for LPS because antibodies to CD14 blocked binding of LPSILPB; however,
because CD 14 anchors without a transmembrane domain, it was also unlikely that
CD 14 alone could activate a signal in response to LPS (Wright 1990). It has been
shown through subsequent studies that TLR4 is the actual LPS receptor (poltorak
1998). The role of CD 14 in TLR4 signaling is that it binds LPS and presents it to
MD-2 and TLR4. It has also been shown that CD14 is important in TLR2 signaling.
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11 acts as a membrane receptor for bacterial products other than LPS, such as
peptidoglycan and lipoarabinomannan, presenting these to TLR2 (Muroi 2002).
The receptor for LPS has been established as TLR4; however, TLR4 also
recognizes lipotechoic acid (LTA), fibronectin, the fusion protein of respiratory
synctial virus (RSV) and taxol, a plant diterpene structurally unrelated to LPS but it
exhibits LPS-mimetic effects on murine cells (Poltorak 1998, Hoshino 1999,
Okamura 2001, Kurt-Jones 2000, Kawasaki 2000). To further complicate LPS
signaling, LPS derived from different strains of bacteria appear to be recognized by
different clusters of receptors, therefore, giving rise to different cellular responses
(Hirschfield 2001). It has been suggested in one study that the shape of the LPS
molecule is critical for a cellular response to LPS and that only LPS with a conically
shaped lipid A portion will act as a ligand for TLR4 (Netea 2002). Lipid A portions
of LPS that are cylindrically shaped, as found in several non-enterobacteria, as well
as precursors and analogues of toxic lipid A from E.coli LPS will bind and activate
TLR2 and may even act as antagonists to TLR4 (Triantafilou 2004). It has also been
demonstrated that less recruitment ofTLR4IMD-2 within lipid rafts leads to
activation of the mitogen-activated protein kinase (MAPK) pathways without
activating NF-kB; therefore, the structure ofLPS is essential for the formation of
specific TLR receptor clusters in response to diverse bacterial products (Triantafilou
2004).
LPS not only causes MD-2/TLR4 to homodimerize, it also causes several other
combinations of signalling proteins to become associated with the receptor complex
which is determined by the form ofLPS bound to MD-2/TLR4. Heat shock proteins
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90 and 70, CD55, CDII/CD18 have been shown as components of the TLR signaling
complex, although, as of yet, the importance of these signaling proteins remains
uncertain (Triantafilou 2001, Byrd 1999, Heine 2003).
The LPS signaling pathways studied most extensively are those activated by TLR4
that make use of adapter proteins: MyD88, Mal, TRIF, and TRAM. Evidence is
emerging that shows the TLR4-mediated response to LPS can be divided into two
categories: an early MyD88-dependent response; and a delayed MyD88-independent
response (Pals son-McDermott 2004).
TLR4 is unique because it acts through both the dependent and independent
pathways, and it has been suggested that the potent inflammatory effects of LPS may
be due to the synergy between these two pathways (Akira 2004). The dependent
pathway uses the adapter molecule MyD88 and leads to early activation ofNF-K~ and
production of cytokines such as TNF-a (Akira 2004). The independent pathway
signals through Toll-IL-IR domain-containing adaptor-inducing
IFN-~

IFN-~

leading to

production (Yamamoto 2002) It also, in a delayed fashion, activates through

NF-K~,

leading to production of inflammatory cytokines (Covert 2005).

It has been observed that pre-treatment with agonists of the dependent pathway

prime inflammatory cytokines and IFN-~ responses to subsequent LPS treatment, and
conversely, cells are tolerized to these agonists when pretreated with LPS (Bagchi
2007). The hypothesis that inhibition of proximal pathways and augmentation of,
distal pathway activity may contribute to tolerance and priming is supported with this
type of response pattern. Therefore, LPS and other dependent pathway agonists may
inhibit the proximal dependent path and increase the activity of distal components of
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both the independent and dependent pathways (Bagchi 2007). The decreased
response to a dependent-specific agonist following exposure to LPS would result
from the signal not getting through the proximal dependent pathway. However, when
cells are treated first with the agonist, despite proximal inhibition of the dependent
pathway, LPS can still access the up-regulated distal pathways via the proximal, noninhibited independent pathway (Bagchi 2007). The interplay between and the
modulation of inflammatory effects of TLRs is highly complex, and studies indicate
that patterns of inflammatory responses to combinations of TLR agonists can be
predicted based on utilization of the dependent and independent pathways (Bagchi
2007). The dependent and independent pathways share some distal intermediaries,
such as TRi\F-6 and NF-K~ (Jiang 2004). However, highly purified TLR agonists
were used, so it is difficult to directly compare these responses with the more
complicated environment that exists in infection (Bagchi 2007).

MyD88-dependent signaling
MyD88 is composed of a C-terminal TIR domain separated from an N-terminal
death domain (DD) (Burns 1998). Protein-protein interactions through other DD
sequences are mediated by this DD. This mechanism is utilized by many signaling
complexes which induce responses such as cytoxicity, activation ofMAPK and
activation oftranscription factors such as NF-K~ (Pals son-McDermott 2004). It was
initially shown that MyD88 associated with the Type I Il-IR (IL-IRI) through its
TIR domain, which was also then shown to occur for TLR4 (Wesche 1997). Studies
using MyD88-1- mice revealed both MyD88-dependent and MyD88-independent
pathways of TLR4 signalling.
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In comparison to wild-type mice, NF -K~ and MAPK activation occurred but was
delayed in MyD88 deficient mice and these mice were resistant to the lethal effects of
LPS. The induction of IFN-~ to LPS was also unaffected (Jiang 2003). The role of
MyD88 as an early responder to LPS was proposed when MyD-88 deficient
splenocytes were incapable of proliferation in response to LPS (poltorak 1998).
Mal, a second adapter protein, was then described in TLR4 signaling (Fitzgerald
2001) and it was thought that it may be the adapter involved in the MyD88independent pathway. Mal knockout mice studies however proved that Mal was an
essential adapter that works together with MyD88 (Oshiumi 2003). Mal-deficient
mice displayed a resistance to the toxic effects of LPS and did not produce TNF, IL-6
or IL-12p40 in response to LPS. These mice also showed a delayed activation ofNFK~

and MAPK in response to LPS, which strengthened the theory that Mal is essential

for, and acts together with, MyD88 (Palsson-McDermott 2004). Mal has been shown
to be·differentially involved in signaling by different TLRs and may provide some of
the specificity in the downstream events of the different receptors (palssonMcDermott 2004). Horng (2002) and Yamamoto (2002) simultaneously showed
that Mal-deficient mice had normal responses to TLR5, TLR7, TLR9, IL-l and IL-18
which suggested that these receptors signal independently fTOm Mal. However, these
mice exhibit impaired responses, not just to LPS but also to the ligand for TLR2
(Horng 2002).
Downstream events in the activation of the MyD88-dependent pathway by LPS,
leading the to the activation ofNF-K~ and the MAPK pathways are shared with the
IL-l pathway which has been well-studied (Pals son-McDermott 2004). The
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activation ofNF-K~, in a simplified model, starts with the association ofIRAK-1 and
IRAK-4 with the receptor complex. Autophosphorylation of IRAK -1 occurs in two
substeps, giving rise to hyperphosphorylated IRAK-1 which casuse dissociation from
the receptor complex and association of IRAK with Traf6 ( (Cao 1996). TRAF6
then becomes activated and associated with TAB-2, which activates the MAPK
kinase TAKI (transforming growth factor-~-activated kinase) which is constitutively
associated with its adapter protein, TAB-I (Ninomiya-Tsuji 1999). At this point,
TAK-l acts as a common activator ofNF-K~, p-38 and c-jun N-terminal kinase
(JNK) pathways (pals son-McDermott 2004). The assembly of a high-molecularweight protein complex known as a signalsome initiates the activation ofNF-K~. The
inhibitory protein K~, made up oflKH-a and

IKB-~,

along with a scaffolding protein

named IKKy (also known as NEMO) make up the signalsome (palsso-McDermott
2004). Eventual phosphorylation of these inhibitory-binding proteins results in their
ubiquitination and degradation, releasing NF-K~ which can then translocate into the
nucleus (Palsson-McDermott 2004) to begin transcription.
MyD88-independent signaling
After both Mal and MyD88 had been shown to be responsible for conveying the
early response to LPS, the adapter (s) for the delayed MyD88-independent pathway
were still missing. TRIF was the next adapter to be identified (Yamomoto 2002) and
it was shown to activate NF-K~ when over-expressed; however, not as potently as the
activation ofNF-K~ by MyD88 and Mal (Palsson-McDermott 2004). Important
evidence for the role ofTRIF in TLR4 signaling came when TRIF-deficient mice
were used to demonstrate the involvement ofTRIF in the MyD88-independent
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pathway in response to LPS. The activation ofNF-K~ in response to LPS in TRIF-/mice was measured and almost normal, although when the cells were deficient in
TRIF as well as MyD88, the NF-K~ response to LPS was totally abolished. TRlF,
most importantly, was also shown to be the sole adapter used by TRL3 (Yamamoto
2003)
Even though these studies established TRIF as a key adapter in the MyD88independent signaling pathway by TLR4, they also showed poor direct interaction
beween TLR4 and TRIF; therefore, the question still remained as to what further
adapter molecule was involved in this pathway. Two different groups independently
identified TRAM as the adapter candidate (Fitzgerald 2003) (Oshiumi 2003).
TRAM was shown to activate IRF-3, IRF-7 and NF-K~ independently of MyD88. It
was also shown to be uniquely required by TLR4 in order to signal which was in
contrast to TRIF that was also required by TLR3 (Fitzgerald 2003). When
measuring the activation ofNF-K~ and

IFN-~

promoter activity, TRAM, on its own,

displays little or no signaling activity; therefore, it has been suggested that it has no
other role than acting as a bridge between TLR4 and TRIF (Oshiumu 2003). It has
also been shown that TRAM cannot interact with TLR2, TLR5, TLR6, TLR7, TLR8
or TLR9 and only weakly, or not at all with TLR3, further evidence for TLR4
specificity. Since they were defective in their response to LPS in a manner similar to
that of the TRIF -1- mice, mice lacking functional TRAM showed that TRAM was
essential for the MyD88-independent signaling pathway in response to LPS
(Yamamoto 2003). The MyD88-dependent pathway appeared to function normally,
whereas the MyD88-independent response to LPS was completely eliminated. The
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MyD88-independent pathway is responsible for the later activation ofNF-K~ and
involves TRIF binding to TRAF6 with the ultimate translocation ofNF-K~ to the
nucleus after ubiquitination and degradation of Ik~ (Sato 2003).
The current simplified working model tor an early MyD88- dependent and later
MyD88 independent-mediated response to LPS is as follows: circulating LBP
recognizes LPS in the plasma and brings it to CD14. With the help ofCD14, LPS
bind to MD-2 and TLR4. This induces homodimerization ofTLR4 which then
recruits MyD88 and Mal to the receptor complex (Palsson-McDerrnott 2004). LPS
signaling leads to the early activation and phosphorylation of IRAK, TRAF 6 becomes
activated, which gives rise to the expression of numerous pro-inflammatory genes.
As a later response to LPS, TLR4 gives rise to the activation ofTRAF6 and TBK1, an
event mediated by the adapters TRIF and TRAM (Pals son-McDermott 2004).
Signaling mechanisms of NF-KB

One of the key factors for osteoclastogenesis, which is induced by osteoblasts, is
RANKL, a member of the tumor necrosis family (Anderson 1997). RANKL was
found to be expressed by T-cells (Wong 1997), and B-cells (Li 2000) as well as
osteoblastic/stromal cells and is essential for osteoclast differentiation. RANK, which
is one of the TNF receptor family members, is expressed in osteoclasts and their
precursor cells as the receptor ofRANKL (Josien 1999). Downstream signaling
through RANK is essential for osteoclastogenesis. Deviation trom the normal
conditions of bone resorption results in bone disease such as periapical osteolysis and
is thought to be caused mainly by infection with Gram-negative bacteria. Such an
infectious and pathological condition induces inflammation, resulting in bone
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resorption due to the modulation of physiological osteoclastogenesis, leading to a
pathological bone resorptive condition (Hotokezka 2007).
There is a body of evidence that suggests that NF -KE plays an important role in
gene regulation during inflammatory and immune reaction (Brand 1996) (Baeuerle
1996) (Barnes 1997). NF -KB regulatory sequences have been found in promoters or
enhancers of numerous genes which encode for pro inflammatory cytokines TNF and
IL-l~,

cytokines, severa] adhesion molecules and procoagulatory protein tissue factor

(Siebenlist 1994) (Brand 1991) (Baldwin 1996). The typical NF -KB dimer consists
of subunits p65 (ReI A) and p50, although other subunits have been identified
(Siebenlist 1994). These complexes are present in an inactive state in the cytosol
bound to inhibitory proteins, collectively termed IKE ( (Siebenlist 1994). Several
IKB proteins have been identified, including IKB-a (Thanos 1995),

IKB-~

(Thompson 1995) and IKB8 (Whiteside 1997). A variety of agents, including factors
such as LPS, TNF-a, and IL-IB, induce the activation ofNF-KB (Muller 1993). A
network ofkinases mediates this activation and is accomplished by the
phosphorylation of II(B, which is thus degraded in an ubiquitin-dependent step by the
proteoasome, a multi catalytic high molecular weight protease system (Thanos 1995).
The translocation of the activated NF -KE dimer into the nucleus is allowed by the
removal of the inhibitor IKB.
The signaling mechanisms that lead to the phosphorylation of IKB, and thereby
NF-KB activation, are only partly understood and characterized for TNF,

Il-l~,

and

LPS (Stancovski 1997, Baeuerle 1998, May 1998, Kirschning 1998 and O'Connell
1998). An IKE kinase (IKK) complex, also named the signalsome, has been
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identified as a true IKB kinase, with several of its active components being cloned,
namely IKK-a"

IKK-~,

and NF-KB-inducing kinase

~NIK)

(DiDonato 1997). Two

adaptor or scaffold proteins have also been found, IKK-y/NF-KB essential modulator
(NEMO)/IKK-associated protein 1 (Rothwarf 1998) and IKK complex-associated
protein (IKAP) (Cohen 1998) which have been suggested to regulate the kinase
activity. Additional kinases, such as mitogen-activated protein kinase/extracellularregulated kinase kinase kinase-l (Lee 1997) or mitogen-activated ribosomal S6
protein kinase (Schouten 1997) may assemble with the signal some following
activation of cells by certain stimuli. For example, activation ofNF-KB by TNF
appears to involve several upstream signaling proteins, which in tum activate NIK,
thereby initiating a signaling pathway that results in IKB phosphorylation (Stancovski
19(7).

LPS and RANKL Common Pathway
It has been suggested that IL-l and RANKL promote the survival of osteoclasts
through NF-KP activation (Jimi 1998). The time course of changes in IKB' s
degradation in preosteoclast (paC) cultures treated with LPS have been shown to be
quite similar to that ofRANKL (Suda 2002). Consistent, with the findings of a
previous study (Jimi 1998), inhibition ofNF-KB activation by lactacystin prevented
the survival of pOCs supported by LPS or RANKL (Suda 2002). Lactacystin is a
specific inhibitor of the 26S proteasome which is involved in the phosphorylation of
the IKB's leading to the translocation ofNFKB's into the nucleus to begin
transcription. These findings suggest that LPS as well as RANKL support the survival
ofpOCs through NF-KP activation (Suda 2002). Degradation oflKB's in pac
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cultures has been shown to be similar to that induced by adding LPS to purified
osteoclast cultures (Suda 2002). These findings suggest that LPS directly acts on
pOCs and elongates their life span through the activation ofNF-KB (Suda 2002).
W ortmannin- a specific P 13k inhibitor - also blocked osteoclast formation; whereas,
PD98059 - a specific MEK inhibitor

failed to affect RANKL- or LPS-induced

osteoclast formation (Suda 2002) which is consistent with our results. Suda suggests
that their results show that the effects ofLPS and RANKL on pOCs must therefore be
mediated not only by NF-KB, but by other signals such as P13/AkT. A lack of
RANKL stimulation in response to LPS also showed that osteoclast formation during
bacterial infection utilizes an alternative mechanism for activation (Coon 2007). In
our study, in addition to the two pathway inhibitors used by Suda (2002), we also
used SB202190

a specific MAPK inhibitor. LY294002 - a specific P13K inhibitor,

and FK506 - a CalcineurinINFAT inhibitor. With the addition of these inhibitors,
there were dramatic reductions in osteoclast formation for both the LPS and RANKL
treated groups. As shown in the Suda study, using the same inhibitor ofthe MEK
kinase pathway, there was no effect on osteoclast formation. Therefore, it can also be
concluded that LPS and RANKL share a common pathway in osteoclast formation.
We also concluded that LPS-stimulated osteoclast formation is mediated through
the TLR4 receptor and not RANK with the use ofOPG and anti-TLR4 antibody.
There is almost complete inhibition of osteoclast formation when cells treated with
RANKL are cultured with OPG; whereas, there is no effect seen with the use of antiTLR4. Conversely, when the LPS group was cultured with OPG, osteoclast
formation occurred; however, when TLR4 was inhibited, there was a reduction in
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osteoclast formation. The possible reasons for incomplete blockage of osteoclast
formation in the LPS and Anti-TLR4 group is there may not have been a high enough
concentration of antibody to block all the receptor sites. Secondly, LPS stimulates
TNF -u secretion which has also been shown to induce osteoclast formation (Jiang
2006). Therefore, we propose that LPS may participate directly in osteoclast
formation. We know that LPS directly stimulates osteoblasts to increase expression
of RANKL. The RANKIRANKL interaction on osteoclast precursor cells can then
sensitize these cells to LPS, which once bound to the TLR4 receptors, can act directly
to induce osteoclast differentiation and activation through a shared pathway.

LPS effects on TNF-a release
LPS and TNF-u are two of the the most potent activators ofNF-KB in cells of the
monocyiic lineage (Siebenlist 1994). However, the signaling cascades leading to
NF-KB activation induced by these stimuli appear to differ markedly (Baeuerle
1998). Studies reveal that a completely different signalsome activation pattern results
from incubation of cells with LPS and TJ'JF-u (Fischer 1999). Incubation of human
monocytic cells with LPS predominantly activated IKK-P with a peak of activation at
30 minutes and a second activation peak at 75 minutes which consisted of both IKK-~
and IKK-u activity. This may be due to continuous stimulation by LPS in the
medium and/or autocrine mechanisms. (Fischer 1999). TJ'JF -u, in contrast, activated
IKK-u preferentially, with a very early peak of activation at 5 minutes (Fischer
1999). The effect ofTNF-u on IKK-P was 3-fold lower than that on IKK-u but
showed a similar time course of activation with no second peak of activation (Fischer
1999). LPS appears to only modestly but preferentially stimulate IKK-P activity over
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a longer time interval, whereas the effect of TNF -u on the IKK molecules is marked
and rapid but appears to be rather limited (Fischer 1999). The effect of LPS on IKK
activity is much weaker than that of ThTF -u which may indicate that the IKK pathway
represents just one of several parallel signaling pathways induced by LPS leading to
NF- KB activation (Fischer 1999). It is also known that LPS is known to initiate
signal transduction cascades resulting in the activation of a network of kinases, Gproteins, cyclic nucleotide metabolizing enzymes, lipid second messengers, and ion
channels, some of which may not even be related to NF~KB (Sweet 1996).
Additional kinases, however. may be involved in LPS-mediated IKB phosphorylation
(Schouten 1997) or a modest but continuous activation ofIKK by LPS may be as
effective as the rapid but short-lived activation of IKK seen following TNF-a
stimulation (Fischer 1999).
It is known that TNF -u, by activating NF -KP, mediates LPS-stimulated
osteoclastogenesis via its p55 receptor (Abu-Amer] 997). In our study, we examined
the effects of LPS on TNF -a release during osteoclast formation with the use of
ELISA. There was a differential response to LPS by monocyies and osteoclasts
which has been shown in other studies (Itoh 2003). Osteoclasts showed a decreased
response to LPS. These results suggest, that in terms of cytokine production in the
presence of LPS, characteristics of monocytes and osteoclasts are quite different from
each other which indicate that osteoclast precursors quit cytokine production (except
for IL-6) in response to LPS as soon as the differentiation pathway of osteoclast
precursors is determined. Loss of inflammatory responsiveness to LPS in osteoclasts
must be requirement for performing essential roles in physiological bone turnover
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(ltoh 2005). Further studies will be necessary to elucidate the mechanism of
regulation of proinflammatory cytokine production in ma,crophages and osteoclasts.
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TNF -(1 stimulation of Osteoclastogenesis
It is known that osteoclasts are derived from hematopoietic precursor cells of the

monocyte-macrophage lineage and that osteoclast precursors produce
proinflammatory cytokines such as TNF-alpha, IL-1Beta, and lL-6 in response to

LPS. The way in which osteoblasts send a second signal to osteoclast precursors in
response to primary osteolytic signals has been the subject of intense investigation. It
is now known that osteoblasts regulate osteoclastogeneis by expressing RANKL
(Yasuda 1998). Osteoclast precursors, which express the RANK, recognize RANKL
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released by osteoblasts. In the presence of other costimulators such as M-CSF,
RANKL stimulates the fusion of osteoclast precursors into multinucleated cells
capable of resorbing bone (Parfitt 1998). Formation of osteoclasts is critical for
normal development because it allows for the formation of the marrow spaces within
bone and the eruption of teeth. Targeted deletion ofRANKL in mice results in severe
osteopetrosis and lack of osteoclasts, due to the inability of osteoblasts to support
osteoclastogenesis (Kong 1999). Failure to produce M-CSF results in mice with
osteopetrotic bone, and both types of genetic failure result in death of the animals
after weaning because of malnutrition secondary to a failure of tooth eruption
(Sundquist 1995). While RANKL has been considered to be a key regulator of
osteoclastogenesis in mice, the paradigm is becoming complicated (Blair 2005).
Many of the TNF-family receptors activate NF-K~ and are reported to replace or
augment RANK signaling, particularly TNF-a receptors (Azuma 2000) (Lam 2000)
(Komabayashi 2000) (Suda 2002) There are studies demonstrating that TNF-a:
induces formation of osteoclast-like cells independent ofRANKL activity
(Kobayashi 2000) (Azuma 2000).
TNF -(1 is a key component in the pathogenesis of inflammatory osteolysis;
however, the way it recruits osteoclasts and promotes bone destruction are not
completely known (Lam 2000). The indirect effect of TNF-(1 via osteoblast signals
through regulation ofRANKL and OPG is an accepted paradigm (Brandstrom
1998),and studies suggest that the RANKIRANKL system in mice and TNF-(1
expression are interdependent. TNF -(1 stimulates expression of the RANK receptor
and RANKL, an action that leads to reciprocal stimulation ofTNF-(1 in a positive

69

feedback manner (Hofbauer 1999, Komine 2001, Zhang 2001);however, controversy
exists as to whether TNF -a can directly stimulate osteoclast differentiation. It has
been shown that TNF-a, in the presence ofM-CSF, is capable of inducing osteoclast
differentiation (Kobayashi 2000) and that TNF -a alone can induce osteoclast
formation and bone resorption (Azuma 2000). Mouse bone marrow cells that were
cultured with M-CSF had formation ofM-CSF bone marrow macrophages appear
within 3 days. Exposure to RANKL or TNF-a stimulated the differentiation of these
macrophages into osteoclasts in the presence ofM-CSF. It has also been reported
that when RANK (-1-) mice had osteotropic factors such as 1,25 (OH)2D3,PTHrP,
and 1L-1 administered, neither TRAP-positive cell formation nor hypercalcemia was
induced (Li 2000). However, induction of TRAP+ cells occurred near the site of
injection with TNF-a administration to RANK (-1-) mice, although the number of
TRAP+ cells was not large. This suggests that TNF-a induces osteoclast
differentiation in the absence of RANK-mediated signals in vivo (Katagiri 2002).
However,consistent with our findings, Lam and associates found that a pure
population of murine osteoclast precursors failed to undergo osteoclastogenesis when
treated vvith TNF-a alone and that a small amount ofRANKL strongly enhanced
osteoclast formation suggesting that osteoclastogenesis induced by TNF -(1 occurred
as a result of direct stimulation of macrophages exposed to a stromal environment
that expressed permissive levels ofRANKL (Lam 2000). Since their observations
were in contrast to Kobayashi and Azmna, who proposed that TNF -(1 treatment of
bone marrow macrophages induces them to acquire the osteoclast phenotype, Lam, et
al. also used the same approach ofthree days of whole marrow culture prior to
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macrophage isolation. Under those circumstances, they also observed that TNF-a
directly induced osteoclast formation. However, when saturating levels of OPO were
added at the initiation of whole bone marrow culture, rather than simultaneously with
the addition ofTNF-a after the initial three day culture period, TNF-a-stimulated
osteoclastogenesis is completely absent (Lam 2000). The study of the mechanisms
of osteoclastogenesis from osteoclasts generated;n culture have been proven to be a
vital tool. In the past, bone resorptive osteoclasts could only be differentiated reliably
in culture by using primary bone marrow, as done by Azuma and Kobayashi. The
marrow cultures contain osteoclast precursors and stromal cells/osteoblasts.
Calcitoriol or parathyroid hormone, which are bone stimulatory agents, induce
osteoblasts in the cultures to indirectly support osteoclast differentiation and activity
by stimulating them to express RANKL (Roodman 1999). Determining whether
exogenously added agents affect osteoclasts directly or indirectly is problematic in
these heterogenous systems. Tn an in vitro culture system using osteoclast precursor
cells purified from various tissues such as bone marrow, spleen, and liver, it is
difficult to avoid contamination with other cell lineages such as T -cells and
mesenchymal stromal cells. In this study, we used RA W264.7-a murine macrophage
cell line that can differentiate into osteoclast-like cells in the presence ofRANKL
(Hsu 1999). There are some characteristic differences between RA W264. 7 cells and
macrophages; for example, RA W264. 7 cells do not respond to

IL-l~,

and the

osteoclast-like cells ditIerentiated from RA W264.7 cells form smaller and shallower
resorption pits on dentin slices than do osteoclasts derived from bone marrow
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macrophages. However the cell line is useful to analyze the detailed mechanisms of
osteoclast differentiation.

LPS dependence on TNFMfl during osteociastogenesis
Factors, such as TNF-a, IL-l, IL-6. parathyroid hormone, vitamin D3, and
prostaglandins. known to stimulate osteoclast formation, bind to receptors on
osteoclast progenitors to induce the release of osteoclast-stimulating factors ( (Boyce
1999). A genetically engineered soluble form ofRANKL, in the presence

ofM~CSF,

induced osteoclast differentiation of progenitors derived from mouse bone marrow
cells, spleen cells, or human peripheral blood mononuclear cells in the absence of
stromal cells/osteoblastic cells (Yasuda] 998). Typical osteopetrosis with complete
occupation of the bone marrow space within endosteal bone is seen in RANKLdeficient mice, demonstrating that RANKL is essential for osteoclast development
(Kong 1999). It has, however, been shown that multinucleation of preosteoclasts
and/or commitment to the osteoclast lineage in the absence of stromal
cells/osteoblastic cells, is induced by several inflammatory cytokines (Jimi 1999). csrc mRNA expression in purified bone marrow macrophages induced by LPS is a
specific marker of commitment to the osteoclast lineage (Abu-Amer 1997). These
findings suggest that osteoclast formation from progenitors can occur through the
direct actions of several cytokines on osteoclast progenitors. Our results from
investigating whether TNF-a can stimulate osteoclast formation directly, showed no
osteoclast formation in cells treated with 50 ng/ml only of TNF -u or 50 ng/ml of
RANKL for only 24 hours. However, with lOng/ml and 50 ng/ml ofTNF-u preceded
by only 24 hours ofRANKL, TRAP+ multinucleated cells were formed in the
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culture. This indicates that TNF-a dose-dependently enhances in vitro
osteoclastogenesis primed by a level of RANKL that is insufficient to induce
osteoclast formation. This is in line with the Lam study. Furthermore, TNF-a
stimulates osteoclastogenesis in circumstances both in vitro and in vivo in which
osteoclast precursors, but not RANKL producing stromal cells are responsive to the
cytokine (Lam 2000). Therefore, TNF -a targets both marrow stromal cells and
osteoclast precursors, but directly impacts the latter only in the presence of
permissive levels ofRANKL. Discrepancies amongst studies can be attributed to the
difference in the type of cell culture, culture conditions, concentrations uses, and the
sensitivity in detection methods. It also reveals the intrinsic complexity in the
regulatory mechanism.
Abu-Amer (1997) reported that LPS administered to wild-type mice promoted
osteoclast formation. In contrast, LPS did not substantially enhance osteoclast
formation in mice lacking the TNFRl, suggesting that LPS-induced
osteoc1astogenesis was mediated by TNF in vivo via this receptor. It was also
reported that TNF-a stimulated the differentiation and survival of osteoclasts by a
mechanism independent of the RANKL-RANK interaction (Kobayashi 2000). Other
studies have shown that TNF-a stimulated multinucleated cell (MNC) formation in
preosteoclast (pOC) cultures (Suda 2002). Such a stimulatory effect of TNF -a was
observed in pOC cultures prepared from TNFR2 -/- mice but not TNFRI-/- mice. In
contrast, LPS similarly induced osteoclast formation in pOC cultures prepared from
both TNFRI-/- and TNFR2-/- mice. These findings suggest that signals mediated by
TNFR 1 rather than TNFR2 were involved in osteoclast formation in TNF -a treated
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pOC cultures, and that LPS promoted the survival and fusion of pOCs independent of
the TNF-a action (Suda 2002).
It has been previously reported that M-CSF stimulated osteoclast formation in

pOC cultures (Takami 1999). In addition to this, anti-c-fins antibody which blocks
the signal from M-CSF did not inhibit LPS-induced osteoclast formation in pOC
cultures (Takami 1999). Thus, it is suggested that LPS stimulates osteoclast
formation, at least in part, via a mechanism that is independent of such factors as
RANKL, TNF, IL-l, and M-CSF, which are known to induce osteoclast formation in
pOC cultures; therefore, not excluding the possibility that LPS-induced osteoclast
formation is mediated by other unknown factors or pathways (Suda 2002). In our
study, we pretreated cells with RANKL for 24 hours and it was removed. The cells
were then treated with TNF-a, additional RANKL or LPS. These cells showed the
expected osteoclast formation. However, the cultures of cells that were pretreated
with the TNF-a antagonist, sTNF RIlFc for 30 minutes showed abolishment or
decreases in osteoclast formation. sTNF RIlFc has been shown to be a potent TNF-a
antagonist (Aggarwal 1996). It blocks TNFRI which has been shown to enhance
osteoclast formation; whereas, TNFR2 has been shown to inhibit osteoclastogenesis
(Abu-Amer 2000). Osteoclast formation stimulated by TNF -a was blocked but
osteoclast formation stimulated by RANKL was not affected. Osteoclast formation
stimulated by LPS deereased 60% which shows that LPS-stimulated
osteoclastogenesis is partially dependent on TNF -u indicating there must be other
mechanisms involved in LPS-induced osteoclastogenesis which is consistent with the
Suda study (Suda 2002). However, it must be kept in mind that TNFR1 and TNFR2-
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activated signaling pathways have been intensively investigated in a variety of other
cell types and the current understanding is primarily based on the studies involving
cells other than osteoclast precursors-osteoclasts. Since many of the pathways
described in the literature, have been shown to be applicable to many different cell
types (Locksley 2001); it is reasonable to assume that a considerable portion of the
signaling cascades described may hold true for osteoclast precursors/osteoclasts
(Feng 2005).
The LPS response system is highly controlled and complex and there are still
major deficiencies in the understanding of the true nature of LPS signaling and how it
might be controlled and regulated. It is still unclear as to how bacteria stimulate bone
pathology and it is accepted that bacterial virulence factors invade into the periapical
tissue and induce local pathology (Nair 1990). The connection between LPS and the
development of periapical lesions and the accompanying bone loss is still
controversial (Hong 2004). A positive correlation between LPS and the presence of
periapical lesions has been reported (Sunqvist 1992). LPS levels in rat periapical
lesions increased with time after lesion induction (Yamasaki 1992). Periapical bone
destruction in dogs is induced with direct application of LPS to dental pulp (Mattison
1987). However, some authors argued about the significance ofLPS in periapical
lesion-induced bone loss in that periapical lesion extracts elicited obvious in vitro
bone resorption, but LPS inhibitor could not alleviate this osteolytic activity
(Stashenko 1992).
Future studies are also needed to evaluate whether these signaling cascades are
indeed employed by oteoclast precursors/osteoclasts to mediate lNF-a dependent
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activation of the NF-KB, JNK, p38, ERK and AkT pathways. Additionally, further
studies will help clarify the intracellular signaling pathways from LPS in
preosteoclasts and osteoclasts, which will contribute to the understanding of the
pathogenesis of inflammation induced bone resorption.
In conclusion, what this data shows is that LPS and RANKL share a common
pathway in the activation of osteoclastogenesis. There is a differential response by
monocytes and pre-osteoclasts during LPS-stimulated TNF-a release. LPSstimulated osteociastogenesis is partially dependent on TNF-a; therefore, there must
be other mechanisms involved independent of this pathway. Lastly, TNF-a cannot
directly induce osteocIastogenesis unless primed by RANKL for at least twenty-four
hours.
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